

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/00, 5/00, 1/20, 9/14, C07H</b> <b>21/04, C12Q 1/68</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/63073</b> <b>(43) International Publication Date:</b> 9 December 1999 (09.12.99)
<b>(21) International Application Number:</b> PCT/US99/11341 <b>(22) International Filing Date:</b> 21 May 1999 (21.05.99) <b>(30) Priority Data:</b> 09/082,737 21 May 1998 (21.05.98) US <b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application</b> US 09/082,737 (CIP) Filed on 21 March 1998 (21.03.98) <b>(71) Applicant (for all designated States except US):</b> THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK [US/US]; West 116th Street and Broadway, New York, NY 10027 (US). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> MINDEN, Audrey [US/US]; Apartment 123, 601 West 115th Street, New York, NY 10025 (US). <b>(74) Agent:</b> WHITE, John, P.; Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY 10036 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> PAK4, A NOVEL GENE ENCODING A SERINE/THREONINE KINASE  <b>(57) Abstract</b> <p>This invention provides an isolated mammalian nucleic acid molecule encoding a PAK4 serine/threonine kinase. This invention provides an isolated nucleic acid molecule encoding a mutant homolog of the mammalian PAK4 serine/threonine kinase whose amino acid sequence is set forth in Figure 1A (SEQ ID NO: 2). This invention provides a fusion protein comprising a PAK4 serine/threonine kinase or a fragment thereof and a second peptide. This invention provides a purified mammalian PAK4 serine/threonine kinase. This invention provides a protein comprising substantially the amino acid sequence set forth in Figure 1A. This invention provides a monoclonal antibody directed to an epitope of a PAK4 serine/threonine kinase. This invention provides a method of inhibiting PAK4 function comprising administering a ligand comprising an amino acid domain which binds to a GTP binding protein so as to inhibit binding of the GTP binding protein to PAK4. This invention provides a method of inhibiting PAK4 function comprising administering a ligand which binds to the GTP binding domain of PAK4 so as to inhibit PAK4 binding to a GTP binding protein. This invention provides a method of inhibiting PAK4 serine/threonine kinase function comprising administering a ligand which blocks an ATP binding domain so as to inhibit PAK4 serine/threonine kinase function. This invention provides a method of inhibiting growth of a tumor cell comprising blocking Cdc42Hs by administering a ligand capable of binding to a Cdc42Hs binding site of a PAK4 serine/threonine kinase.</p>		

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PAK4, A NOVEL GENE ENCODING A SERINE/THREONINE KINASE

5 This application is a continuation-in-part application of U.S. Serial No. 09/082,737 filed March 21, 1998, the contents of which is hereby incorporated by reference.

10 Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic citation for these references may be found at the end of this application, preceding the claims.

15 BACKGROUND OF THE INVENTION

20 The GTPases Rac and Cdc42Hs control diverse cellular functions. In addition to being mediators of intracellular signaling cascades, they have important roles in cell morphogenesis and mitogenesis. A novel PAK related kinase, PAK4, has been identified as a new effector molecule for Cdc42Hs. PAK4 interacts only with the activated form of Cdc42Hs through its GTPase binding domain (GBD). Co-expression of PAK4 and the constitutively active Cdc42HsV12 cause the re-distribution of PAK4 to the Brefeldin A sensitive compartment of the Golgi membrane and the subsequent induction of filopodia and actin polymerization. Importantly, the reorganization of the actin cytoskeleton was dependent on PAK4 kinase activity and on its interaction with Cdc42Hs. Thus, unlike other members of the PAK family, PAK4 provides a novel link between Cdc42Hs and the actin cytoskeleton. The cellular locations of PAK4 and Cdc42Hs suggests a role for the Golgi in cell morphogenesis.

35

Members of the Rho family of small GTPases Rac and Cdc42Hs have been implicated in diverse biological processes. These include roles in cell proliferation, progression through

-2-

the cell cycle, and oncogenic transformation (Van Aelst and D'Souza-Schorey, 1997). Cdc42Hs and Rac also play important roles in signal transduction cascades such as those that lead to activation of both the JNK and the p38 families of MAP kinases, and thus lead to long term changes in gene expression (Bagrodia et al., 1995; Brown et al., 1996; Coso et al., 1995; Minden et al., 1995; Zhang et al., 1995). One of the most important functions of Rac and Cdc42Hs is the regulation of the organization of the actin cytoskeleton. Microinjection of Cdc42Hs into fibroblasts and a variety of other cell types causes the induction of filopodia protrusions followed by the formation of lamellipodia. While the induction of filopodia is caused by Cdc42Hs activation, the induction of lamellipodia is probably due to the ability of Cdc42Hs to activate Rac. Thus, co-expression of Cdc42Hs with a dominant negative Rac mutant results in the sustained induction of filopodia without the subsequent induction of lamellipodia. Furthermore, microinjection of activated Rac leads to the induction of lamellipodia, but not filopodia. In addition to the formation of polymerized actin structures, both Cdc42Hs and Rac induce the formation of focal complexes that are associated with the filopodia and lamellipodia. Finally, in some cells, both Cdc42Hs and Rac have been shown to have a role in the dissolution of stress fibers, which may be due to antagonism between these GTPases and a third GTPase, RhoA.

A great deal of effort has been made to identify the downstream molecular targets for Rac and Cdc42Hs. Several proteins were shown to interact with the activated forms of Rac and Cdc42Hs including PAK65, p67-phox, WASP, IQGAP, and MLK3 (Manser et al. 1994, Martin et al. 1995; Bagrodia et al.; 1995, Aspenstrom et al., 1996; Rana et al., 1996; Symons et al., 1996; Hart et al. 1996; Kuroda et al. 1996; Teramoto et al., 1996; Burbelo et al. 1995; Van Aelst et al., 1996). PAK was the first protein kinase that was shown to be a target for Rac and Cdc42Hs, and consequently

-3-

drew much attention. Activated Rac and Cdc42Hs stimulate PAK autophosphorylation and stimulate its kinase activity. Several PAK family members have been identified and all were shown to interact with GTP bound forms of Rac and Cdc42Hs. These include human PAK1 and 2, mouse PAK3, and the rat homologues PAK  $\alpha$ ,  $\beta$ , and  $\gamma$  (Brown et al., 1996; Manser et al., 1994; Martin et al., 1995; Bagrodia et al., 1995). The PAKs are all similar in structure, containing an amino terminal regulatory domain and a carboxyl terminal kinase domain. They are also all quite similar in sequence, exhibiting 73% overall sequence identity and approximately 92% sequence identity within the kinase domain (Sells and Chernof, 1997). The regulatory domains of the PAKs contain a GTPase binding domain GBD (Symons et al., 1996) (known also as Cdc42Hs/Rac Interactive Binding (CRIB) domain) (Burbelo et al., 1995) that is necessary and essential for their direct interaction with both Cdc42Hs and Rac.

The functions of the PAKs are not yet entirely known. The sequence similarities between the PAKs and yeast STE20, however, suggests a role in transcription activation or cell morphogenesis. In Saccharomyces cerevisiae, STE20 is activated by Cdc42p, and is an important component of the KSS/FUS3 MAP Kinase pathway. STE20 and the related CLA4 may also mediate cytoskeletal changes induced by Cdc42p, such as those that occur during cytokinesis. Because of the evolutionary conservation between many yeast and mammalian signaling enzymes, it seems likely that the PAKs may have functions similar to the yeast STE20 and CLA4 proteins. In fact, the PAKs have been shown to weakly activate the JNK MAP kinase pathway in some cells (Bagrodia et al., 1995; Brown et al., 1996; Zhang et al., 1995). This suggests that, like STE20, the PAKs may be involved in MAP Kinase pathways. Some groups have shown however, that the PAKs are not necessary for JNK activation, and thus their roles in MAP Kinase pathways are as yet unclear. The PAKs may also be involved in cytoskeletal organization. PAK1 was reported to induce filopodia and membrane ruffles similar to those

-4-

induced by Cdc42Hs and Rac, and to localize to polymerized actin. Interestingly however, these cytoskeletal changes are partly independent of PAK1's kinase activity, and they also occur independently of PAK1's ability to bind the Rho GTPases. Thus, while overexpressed PAK1 can promote cytoskeletal changes, it may not specifically mediate the cytoskeletal changes induced by Rac and Cdc42Hs. Others have found that PAK1 does not induce filopodia or lamellipodia but instead has a role in the dissolution of stress fibers and down-regulation of focal adhesions. Finally, effector mutants of Rac and Cdc42Hs, (such as RacL61(Y40C) and Cdc42HsL61(Y40C)) that do not bind the PAKs, maintain the ability to induce lamellopodia and filopodia. Taken together, these results suggest that the induction of lamellipodia and filopodia by Rac and Cdc42Hs can occur independently of the known PAKs.

Here the cloning and characterization of a novel serine/threonine kinase, PAK4 is reported. Like other members of the PAK family, PAK4 contains an amino terminal regulatory domain and a carboxyl terminal kinase domain. The kinase domain of PAK4 shares 53% sequence identity with those of the other PAKs. Outside of this region however, PAK4 is entirely different in sequence from the other PAKs, except for a short stretch containing a modified GBD motif. PAK4 is the first member of the PAK family to be identified that differs significantly in sequence from the other PAKs, and thus represents an entirely new member of the PAK family. PAK4 interacts specifically with the GTP bound form of Cdc42Hs via its GBD motif and weakly activates the JNK family of MAP kinases. Co-expression of PAK4 with Cdc42Hs causes PAK4 to translocate from a diffuse perinuclear area to the Golgi membrane and subsequently induced the formation of filopodia and actin polymerization. Thus, the Golgi translocation of PAK4 by Cdc42Hs may be important for its ability to induce filopodia. Furthermore, PAK4 interacts with the Cdc42Hs effector mutant, Cdc42HsL61(Y40C) that was previously was

-5-

shown to induce filopodia independently of PAKs. These results indicate therefore, that PAK4, rather than the previously identified PAKs, provides a link between Cdc42Hs and the actin cytoskeleton.

-6-

## SUMMARY OF THE INVENTION

This invention provides an isolated mammalian nucleic acid molecule encoding a PAK4 serine/threonine kinase.

5

This invention provides an isolated nucleic acid molecule encoding a mutant homolog of the mammalian PAK4 serine/threonine kinase whose amino acid sequence is set forth in Figure 1A (SEQ ID NO: 2).

10

This invention provides a fusion protein comprising a PAK4 serine/threonine kinase or a fragment thereof and a second peptide.

15

This invention provides a purified mammalian PAK4 serine/threonine kinase.

This invention provides a protein comprising substantially the amino acid sequence set forth in Figure 1A.

20

This invention provides a monoclonal antibody directed to an epitope of a PAK4 serine/threonine kinase.

25

This invention provides a method of inhibiting PAK4 function comprising administering a ligand comprising an amino acid domain which binds to a GTP binding protein so as to inhibit binding of the GTP binding protein to PAK4.

30

This invention provides a method of inhibiting PAK4 function comprising administering a ligand which binds to the GTP binding domain of PAK4 so as to inhibit PAK4 binding to a GTP binding protein.

35

This invention provides a method of inhibiting PAK4 serine/threonine kinase function comprising administering a ligand which blocks an ATP binding domain so as to inhibit PAK4 serine/threonine kinase function.

-7-

This invention provides a method of inhibiting growth of a tumor cell comprising blocking Cdc42Hs by administering a ligand capable of binding to a Cdc42Hs binding site of a PAK4 serine/threonine kinase.

## BRIEF DESCRIPTION OF THE FIGURES

**Figure 1A-1E.** Sequence and expression pattern of PAK4.

5                    Fig. 1A-B. Nucleotide sequence of PAK4, a  
                    novel serine/threonine kinase (SEQ ID NO: 1  
                    and SEQ ID NO: 2). The CRIB domain (amino  
                    acids 1-30) and the kinase domain (amino  
10                   acids 323-574) are underlined. Figure 1C.  
                    Alignment of the kinase domain of PAK4 with  
                    those of PAK2 and STE20 (SEQ ID NO: 3, SEQ  
                    ID NO: 4 and SEQ ID NO: 5, respectively).  
                    Fig. 1D. Alignment of the GBD/CRIB motif of  
15                   PAK4 (SEQ ID NO: 6) with the corresponding  
                    regions of several other mammalian (PAK2  
                    (SEQ ID NO: 7) and WASP (SEQ ID NO: 9)) and  
                    yeast (STE20 (SEQ ID NO: 8) and CLA4 (SEQ ID  
                    NO: 10)) Rac and Cdc42Hs interacting  
                    proteins. Fig. 1E. Northern blot analysis of  
20                   PAK4. A Northern blot containing mRNA from  
                    various human tissues was probed with a cDNA  
                    containing the kinase domain of PAK4. A band  
                    of approximately 3 KB is indicated.

25           **Figures 2A-2B.** PAK4 interacts with the activated Cdc42Hs  
                    through its GBD/CRIB domain.

                    Fig. 2A. Recombinant PAK4 and hPAK2 (2-3  $\mu$ g)  
                    were analyzed by the overlay assay and  
30                   probed with the indicated GTPase preloaded  
                    with either [ $\gamma$ <sup>32</sup>P]GTP or <sup>32</sup>[ $\beta$  P]GDP as  
                    described in materials and methods. Fig.  
                    2B. Cos-1 cells were transiently transfected  
                    with expression vectors containing HA tagged  
35                   PAK4 or PAK4 $\Delta$ GBD, (a deletion mutant lacking  
                    the GBD/CRIB domain). After transient  
                    expression, Cos-1 cells were harvested,  
                    immunopurified with the anti HA antibodies,

-9-

separated by SDS PAGE and transferred to nylon membranes. Binding of PAK4 or PAK4DGBD to  $[\gamma\text{-}^{32}\text{P}]\text{GTP}$  loaded Cdc42Hs was assessed as in Fig. 2A. To ensure that both wild-type PAK4 and PAK4 $\Delta$ GDBD were expressed at approximately equivalent levels, cell extract (25  $\mu\text{g}$ ) was analyzed by Western Blots probed with anti HA antibody.

10      **Figures 3A-3B. Analysis of PAK4 kinase activity.**

Fig. 3A. NIH3T3 cells were transfected with either empty Sra vector (control) or with increasing doses of Sra expression vectors containing the PAK cDNA fused to an HA epitope tag (0.5 and 1  $\mu\text{g}$ ). After transient expression, PAK4 was immunopurified from cell lysates using anti HA antibody. Immunopurified PAK4 was incubated with Histone H4, or without any substrate in the presence of  $[\gamma\text{-}^{32}\text{P}]\text{ATP}$  and kinase buffer (Minden et al., 1994). Substrate phosphorylation was analyzed after SDS PAGE and autoradiography. Autophosphorylation of the 70 kDa PAK4 and a band of approximately 43 kDa that co-purifies with PAK4 is indicated. Fig. 3B. Cos-1 cells were transfected with 1  $\mu\text{g}$  of expression vectors containing either wild-type PAK4 or the indicated PAK4 mutants, all fused to HA tags. After transient expression, immunopurified PAK4 was used to phosphorylate Histone H4 in the presence of kinase buffer and  $[\gamma\text{-}^{32}\text{P}]\text{ATP}$ . Substrate phosphorylation is indicated. Similar results were obtained with NIH3T3 cells. Figs. 3C-3E. NIH3T3 cells were transfected with empty Sra vector (control) or

-10-

increasing doses of Src myc tagged PAK4 expression vector (0.2, 0.6, or 1  $\mu$ g) together with 1  $\mu$ g of HA tagged JNK, ERK, or p38 expression vectors. As positive controls, cells were either transfected with expression vectors for Rac2L61 or RasV12 or treated with 400 mM sorbitol, as indicated. After transient expression, JNK, ERK, or p38 were immunopurified from cell lysates using anti HA antibody. Immunopurified proteins were incubated in kinase buffer and [ $\gamma$ -<sup>32</sup>P]ATP together with either GST-cJun, GST-ATF2, or MBP as substrates, respectively (Minden et al., 1995). Substrate phosphorylation was visualized after SDS PAGE and autoradiography. Substrate phosphorylation was quantitated by phosphorimager analysis. The numbers indicated are the averages of three independent experiments.

**Figures 4A-4J. Localization of PAK4 and its effects on the actin cytoskeleton.**

Figs. 4A-4F. Porcine endothelial cells (PAE) were microinjected with HA tagged PAK4 expression vector alone or in combination with Myc tagged Cdc42HsV12 or RacV12 expression vectors (50 ng/ $\mu$ l plasmid). Cells were fixed 11-14 hours after injection and PAK4 was visualized by immunofluorescence microscopy after staining with FITC tagged HA antibody. Polymerized actin was visualized after staining with Rhodamine conjugated phalloidin. Figs. 4G-4J. PAE cells were microinjected with Myc tagged PAK2 expression vector alone and in combination with Cdc42HsV12 or RacV12

-11-

expression vectors. Polymerized actin was visualized as described in Figs. 4A-4F. Arrows indicate the injected cells.

5      **Figures 5A-5H**   PAK4 is recruited by Cdc42Hs to the BFA sensitive compartment of the Golgi.

10                      PAE cells were microinjected with HA tagged PAK4 expression vector alone or in combination with Cdc42HsV12 expression vector. After 12-16 hours cells were either left untreated or treated with 5  $\mu$ g/ml BFA for 3-5 min. at 37°C followed immediately by fixation. b-COP was visualized by a specific antibody against b-COP protein (Gift of Richard Khan). To compare the localization of PAK4 to b-COP compare fluorescence micrograph of anti HA staining to that of anti b-COP staining.

20

**Figures 6A-6H.** PAK4 localization to the Golgi and kinase activity are essential for actin polymerization.

25

Fluorescence micrographs of PAE cells microinjected with expression vectors containing HA tagged kinase inactive PAK4(M430) or the PAK4(E474) mutant, alone or in combination with Cdc42HsV12 expression vector. PAK4 was detected by HA antibody and polymerized actin was visualized by phalloidin staining.

30

**Figures 7A-7C.** Analysis of Cdc42Hs effector mutants.

35

Fig. 7A. Recombinant PAK4, hPAK2, and WASP (2-3  $\mu$ g) were analyzed by the overlay assay and probed with the indicated Cdc42Hs mutant

-12-

preloaded with [ $\gamma^{32}$ P]GTP (Martin et al., 1995). Figs. 7B-7C. Porcine endothelial cells (PAE) were injected with HA tagged PAK4 expression vector alone or in combination with Myc tagged Cdc42HsL61(C40) mutant. (100 ng/ $\mu$ l plasmid). Cell were fixed 11-14 hours after injection and PAK4 was visualized by immunofluorescence microscopy after staining with FITC tagged HA antibody.

**Figure 8A-8C**

Fig. 8A. Partial cDNA of the mouse PAK4 (SEQ ID NO: 13). Fig. 8B. Predicted amino acid sequence of the partial mouse PAK4 cDNA (SEQ ID NO: 14). Fig. 8C. Partial genomic sequence of mouse PAK4 (SEQ ID NO: 15).

-13-

## DETAILED DESCRIPTION OF THE INVENTION

The following standard abbreviations are used throughout the specification to indicate specific nucleotides:

5

C=cytosine      A=adenosine  
T=thymidine    G=guanosine

10 This invention provides an isolated nucleic acid molecule encoding a PAK4 serine/threonine kinase. In an embodiment the isolated nucleic acid molecule encoding a PAK4 serine/threonine kinase is a DNA molecule. In another embodiment the isolated nucleic acid molecule encoding a PAK4 serine/threonine kinase is a cDNA molecule. In a  
15 further embodiment the isolated DNA molecule encoding a PAK4 serine/threonine kinase is a genomic DNA molecule. In an embodiment the isolated nucleic acid molecule encoding a PAK4 serine/threonine kinase is an RNA molecule.

20 The DNA molecules of the subject invention also include DNA molecules coding for polypeptide analogs, fragments or derivatives of antigenic polypeptides which differ from naturally-occurring forms in terms of the identity or location of one or more amino acid residues (deletion  
25 analogs containing less than all of the residues specified for the protein, substitution analogs wherein one or more residues specified are replaced by other residues and addition analogs where in one or more amino acid residues is added to a terminal or medial portion of the  
30 polypeptides) and which share some or all properties of naturally-occurring forms. These molecules include: the incorporation of codons "preferred" for expression by selected non-mammalian hosts; the provision of sites for cleavage by restriction endonuclease enzymes; and the  
35 provision of additional initial, terminal or intermediate DNA sequences that facilitate construction of readily expressed vectors.

-14-

The DNA molecules described and claimed herein are useful for the information which they provide concerning the amino acid sequence of the polypeptide, PAK4 serine/threonine kinase, and as products for the large scale synthesis of the polypeptide (PAK4 serine/threonine kinase) by a variety of recombinant techniques. The molecule is useful for generating new cloning and expression vectors, transformed and transfected prokaryotic and eukaryotic host cells, and new and useful methods for cultured growth of such host cells capable of expression of the polypeptide (PAK4 serine/threonine kinase) and related products.

In another embodiment of the isolated nucleic acid molecule encoding a PAK4 serine/threonine kinase, the nucleic acid molecule encodes a mammalian PAK4 serine/threonine kinase. In a preferred embodiment of the isolated nucleic acid molecule encoding a PAK4 serine/threonine kinase, the mammalian PAK4 serine/threonine kinase is a human, mouse or rat PAK4 serine/threonine kinase. In a further embodiment of the isolated nucleic acid molecule encoding a mammalian PAK4 serine/threonine kinase, the nucleic acid molecule encodes a PAK4 serine/threonine kinase comprising an amino acid sequence as set forth in Figure 1A (SEQ ID NO: 2). In an embodiment of the isolated nucleic acid molecule encoding a PAK4 serine/threonine kinase comprising an amino acid sequence as set forth in Figure 1A (SEQ ID NO: 2), the encoded amino acid sequence comprises a GTPase binding domain (GBD). In another embodiment of the isolated nucleic acid molecule encoding the mammalian PAK4 serine/threonine kinase, the PAK4 serine/threonine kinase has substantially the same amino acid sequence as set forth in Figure 1A (SEQ ID NO: 2).

In a further embodiment of the isolated nucleic acid molecule encoding the mammalian PAK4 serine/threonine kinase, the encoded PAK4 serine/threonine kinase has the amino acid sequence as set forth in Figure 1A (SEQ ID NO: 2).

-15-

This invention provides an isolated nucleic acid molecule encoding a mutant homolog of the mammalian PAK4 serine/threonine kinase whose amino acid sequence is set forth in Figure 1A (SEQ ID NO: 2). In an embodiment the isolated nucleic acid molecule encoding the above-described mutant homolog of the mammalian PAK4 serine/threonine kinase is a deletion mutant. In a further embodiment of the deletion mutant, the encoded mutant homolog comprises a GTPase binding domain. In a still further embodiment of the deletion mutant, the encoded mutant homolog does not comprise a GTPase binding domain. In an embodiment of the isolated nucleic acid molecule encoding the mammalian PAK4 serine/threonine kinase, the mammalian PAK4 serine/threonine kinase comprises the nucleic acid sequence set forth in Figure 1A (SEQ ID NO:1).

This invention provides a fusion protein comprising a PAK4 serine/threonine kinase or a fragment thereof and a second peptide. Fusion of a peptide with a smaller peptide, for example, a tag such as a hemagglutinin (HA) or myc tag, is well known to one of ordinary skill in the art.

This invention provides a vector comprising the mammalian nucleic acid molecule encoding a PAK4 serine/threonine kinase. In an embodiment the vector is adapted for expression in a host cell which comprises the regulatory elements necessary for expression of the nucleic acid molecule in the host cell operatively linked to the nucleic acid molecule encoding the PAK4 serine/threonine kinase as to permit expression of the PAK4 serine/threonine kinase. In another embodiment of the vector, the host cell is a eukaryotic, bacterial, insect or yeast cell. In a further embodiment of the vector, the eukaryotic host cell is a mammalian cell. In a still further embodiment the vector is a plasmid.

This invention also provides a vector comprising the

-16-

nucleic acid molecule encoding a mammalian PAK4 serine/threonine kinase, wherein the nucleic acid molecule is a cDNA molecule. In an embodiment the vector is adapted for expression in a host cell which comprises the regulatory elements necessary for expression of the nucleic acid molecule in the host cell operatively linked to the nucleic acid molecule encoding the PAK4 serine/threonine kinase as to permit expression of the PAK4 serine/threonine kinase. In another embodiment of the vector, the host cell is a eukaryotic, bacterial, insect or yeast cell. In a further embodiment of the vector, the eukaryotic host cell is a mammalian cell. In a still further embodiment the vector is a plasmid.

In an embodiment, a full-length cDNA nucleic acid molecule encoding a human PAK4 serine/threonine kinase is inserted by subcloning into a SR $\alpha$  plasmid and the resulting plasmid is designated as SR $\alpha$ HAPAK4. Plasmid SR $\alpha$ HAPAK4 was deposited on May 21, 1998 with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, VA 20110-2209, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. Plasmid SR $\alpha$ HAPAK4 was accorded ATCC Accession Number 209888.

Numerous vectors for expressing the inventive proteins may be employed. Such vectors, including plasmid vectors, cosmid vectors, bacteriophage vectors and other viruses, are well known in the art. For example, one class of vectors utilizes DNA elements which are derived from animal viruses such as bovine papilloma virus, polyoma virus, adenovirus, vaccinia virus, baculovirus, retroviruses (RSV, MMTV or MoMLV), Semliki Forest virus or SV40 virus. Additionally, cells which have stably integrated the DNA into their chromosomes may be selected by introducing one or more markers which allow for the selection of transfected host cells. The markers may provide, for

-17-

example, prototrophy to an auxotrophic host; biocide resistance or resistance to heavy metals such as copper. The selectable marker gene can be either directly linked to the DNA sequences to be expressed, or introduced into the same cell by cotransformation.

Regulatory elements required for expression include promoter sequences to bind RNA polymerase and transcription initiation sequences for ribosome binding. Additional elements may also be needed for optimal synthesis of mRNA. These additional elements may include splice signals, as well as enhancers and termination signals. For example, a bacterial expression vector includes a promoter such as the lac promoter and for transcription initiation the Shine-Dalgarno sequence and the start codon AUG. Similarly, a eukaryotic expression vector includes a heterologous or homologous promoter for RNA polymerase II, a downstream polyadenylation signal, the start codon AUG, and a termination codon for detachment of the ribosome. Such vectors may be obtained commercially or assembled from the sequences described by methods well known in the art, for example the methods described above for constructing vectors in general.

These vectors may be introduced into a suitable host cell to form a host vector system for producing the inventive proteins. Methods of making host vector systems are well known to those skilled in the art.

Suitable host cells include, but are not limited to, bacterial cells (including gram positive cells), yeast cells, fungal cells, insect cells and animal cells. Suitable animal cells include, but are not limited to HeLa cells, Cos cells, CV1 cells and various primary mammalian cells. Numerous mammalian cells may be used as hosts, including, but not limited to, the mouse fibroblast cell NIH-3T3 cells, CHO cells, HeLa cells, Ltk<sup>-</sup> cells and COS cells. Mammalian cells may be transfected by methods well

-18-

known in the art such as calcium phosphate precipitation, electroporation and microinjection.

5 One of ordinary skill in the art will easily obtain unique sequences from the cDNA cloned in the S $\alpha$  plasmid. Such unique sequences may be used as probes to screen various mammalian cDNA libraries and genomic DNAs, e.g. mouse, rat and bovine, to obtain homologous nucleic acid sequences and to screen different cDNA tissue libraries to obtain  
10 isoforms of the obtained nucleic acid sequences. Nucleic acid probes from the cDNA cloned in the S $\alpha$  plasmid may further be used to screen other human tissue cDNA libraries to obtain isoforms of the nucleic acid sequences encoding PAK4 serine/threonine kinase as well as to screen human  
15 genomic DNA to obtain the analogous nucleic acid sequences. The homologous nucleic acid sequences and isoforms may be used to produce the proteins encoded thereby.

20 This invention provides a plasmid comprising the nucleic acid molecule encoding a human PAK4 serine/threonine kinase designated S $\alpha$ HAPAK4 (ATCC Accession No. 209888).

25 This invention provides a nucleic acid probe comprising a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a unique sequence included within the sequence of an isolated nucleic acid molecule encoding a mammalian PAK4 serine/threonine kinase. The nucleic acid probe may hybridize to any of the above-described isolated full-length nucleic acid molecules  
30 encoding a mammalian PAK4 serine/threonine kinase or fragments thereof.

35 This invention provides a nucleic acid probe comprising a nucleic acid molecule of at least 15 nucleotides which is complementary to a sequence of the isolated nucleic acid molecule encoding a mammalian PAK4 serine/threonine kinase.

The nucleic acid probe is complementary to a sequence of

-19-

any of the above-described isolated full-length nucleic acid molecules encoding a mammalian PAK4 serine/threonine kinase or fragments thereof.

5 This invention provides a method of producing a PAK4 serine/threonine kinase, which comprises growing a host cell comprising any of the above-described vectors under suitable conditions permitting production of the PAK4 serine/threonine kinase and recovering the PAK4  
10 serine/threonine kinase so produced. In an embodiment the method further comprises purifying the recovered PAK4 serine/threonine kinase.

This invention provides a method of producing a polypeptide  
15 having the biological activity of a protein encoded by the nucleic acid molecule encoding a PAK4 serine/threonine kinase which comprises growing the above-described host cells under suitable conditions permitting production of the polypeptide and recovering the polypeptide so produced.  
20 In another embodiment the method further comprises purifying the recovered polypeptide.

This invention provides a purified mammalian PAK4 serine/threonine kinase. In an embodiment the purified  
25 mammalian PAK4 serine/threonine kinase is a human PAK4 serine/threonine kinase.

This invention provides a protein comprising substantially the amino acid sequence set forth in Figure 1A.  
30

This invention provides an oligonucleotide comprising a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a unique sequence included within the sequence of the isolated nucleic acid molecule  
35 encoding a mammalian PAK4 serine/threonine kinase. In an embodiment of the oligonucleotide the nucleic acid is DNA. In another embodiment of the oligonucleotide the nucleic acid is RNA.

-20-

This invention provides an antisense oligonucleotide comprising a sequence capable of specifically hybridizing with a unique sequence included within the mRNA molecule encoding a mammalian PAK4 serine/threonine kinase.

5

This invention provides an antisense oligonucleotide comprising a sequence capable of specifically hybridizing with a unique sequence included within the genomic DNA molecule encoding a mammalian PAK4 serine/threonine kinase.

10

This invention provides an antibody capable of binding to the PAK4 serine/threonine kinase which may be a purified mammalian PAK4 serine/threonine kinase or a purified human PAK4 serine/threonine kinase. In an embodiment the antibody is a monoclonal antibody. In another embodiment the antibody is a polyclonal antibody.

15

This invention provides a monoclonal antibody directed to an epitope of a PAK4 serine/threonine kinase.

20

Polyclonal antibodies may be produced by injecting a host animal such as rabbit, rat, goat, mouse or other animal with the immunogen of this invention, e.g. a purified mammalian PAK4 serine/threonine kinase or a purified human PAK4 serine/threonine kinase. The sera are extracted from the host animal and are screened to obtain polyclonal antibodies which are specific to the immunogen. Methods of screening for polyclonal antibodies are well known to those of ordinary skill in the art such as those disclosed in Harlow & Lane, Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratories, Cold Spring Harbor, NY: 1988) the contents of which are hereby incorporated by reference.

25

30

35

The monoclonal antibodies may be produced by immunizing for example, mice with an immunogen. The mice are inoculated intraperitoneally with an immunogenic amount of the above-described immunogen and then boosted with similar amounts

-21-

of the immunogen. Spleens are collected from the immunized mice a few days after the final boost and a cell suspension is prepared from the spleens for use in the fusion.

5 Hybridomas may be prepared from the splenocytes and a murine tumor partner using the general somatic cell hybridization technique of Kohler, B. and Milstein, C., Nature (1975) 256: 495-497. Available murine myeloma lines, such as those from the American Type Culture  
10 Collection (ATCC) 10801 University Boulevard, Manassas, VA 20110-2209 USA, may be used in the hybridization. Basically, the technique involves fusing the tumor cells and splenocytes using a fusogen such as polyethylene glycol. After the fusion the cells are separated from the  
15 fusion medium and grown in a selective growth medium, such as HAT medium, to eliminate unhybridized parent cells. The hybridomas may be expanded, if desired, and supernatants may be assayed by conventional immunoassay procedures, for example radioimmunoassay, using the immunizing agent as  
20 antigen. Positive clones may be characterized further to determine whether they meet the criteria of the invention antibodies.

Hybridomas that produce such antibodies may be grown in vitro or in vivo using known procedures. The monoclonal  
25 antibodies may be isolated from the culture media or body fluids, as the case may be, by conventional immunoglobulin purification procedures such as ammonium sulfate precipitation, gel electrophoresis, dialysis,  
30 chromatography, and ultrafiltration, if desired.

In the practice of the subject invention any of the above-described antibodies may be labeled with a detectable marker. In one embodiment, the labeled antibody is a  
35 purified labeled antibody. The term "antibody" includes, by way of example, both naturally occurring and non-naturally occurring antibodies. Specifically, the term "antibody" includes polyclonal and monoclonal antibodies,

-22-

and fragments thereof. Furthermore, the term "antibody" includes chimeric antibodies and wholly synthetic antibodies, and fragments thereof. A "detectable moiety" which functions as detectable labels are well known to those of ordinary skill in the art and include, but are not limited to, a fluorescent label, a radioactive atom, a paramagnetic ion, biotin, a chemiluminescent label or a label which may be detected through a secondary enzymatic or binding step. The secondary enzymatic or binding step may comprise the use of digoxigenin, alkaline phosphatase, horseradish peroxidase,  $\beta$ -galactosidase, fluorescein or streptavidin/biotin. Methods of labeling antibodies are well known in the art.

This invention provides a method of inhibiting PAK4 function comprising administering a ligand comprising an amino acid domain which binds to a GTP binding protein so as to inhibit binding of the GTP binding protein to PAK4.

As used herein, PAK4 is a PAK4 serine/threonine kinase. As used herein, PAK4 function is defined as an effector for Cdc42Hs which mediates induction of filopodia.

This invention provides a method of inhibiting PAK4 function comprising administering a ligand which binds to the GTP binding domain of PAK4 so as to inhibit PAK4 binding to a GTP binding protein.

This invention provides a method of inhibiting PAK4 serine/threonine kinase function comprising administering a ligand which blocks an ATP binding domain so as to inhibit PAK4 serine/threonine kinase function.

As used herein ligands comprising an amino acid domain which binds to a GTP binding protein, which binds to the GTP binding domain of PAK4, or which block an ATP binding domain are defined as an amino acid molecule or fragment thereof which has an amino acid sequence complementary to

-23-

a GTP binding protein, GTP binding domain of PAK4, or an ATP binding domain, respectively.

5 In an embodiment of any of the above-described methods of inhibiting PAK4 function, the inhibition of PAK4 function thereby inhibits polymerization of actin cytoskeleton. As used herein any of the above-described methods may be used to inhibit tumor cell growth.

10 In an embodiment of the method of inhibiting PAK4 function comprising administering a ligand comprising an amino acid domain which binds to a GTP binding protein so as to inhibit binding of the GTP binding protein to PAK4 or the method of inhibiting PAK4 function comprising administering  
15 a ligand which binds to the GTP binding domain of PAK4 so as to inhibit PAK4 binding to a GTP binding protein, the GTP binding protein is Cdc42Hs or Rac. In an embodiment of either of these methods the method may further comprise inhibition of induction of filopodia. The ligand which  
20 inhibits PAK4 function may thus inhibit cytokine pathways, e.g. TNF $\alpha$  and growth factor pathways, e.g. epidermal growth factor (EGF).

25 In an embodiment of the method of inhibiting PAK4 function comprising administering a ligand which binds to the GTP binding domain of PAK4 so as to inhibit PAK4 binding to a GTP binding protein or the method of inhibiting PAK4 serine/threonine kinase function comprising administering  
30 a ligand which blocks an ATP binding domain so as to inhibit PAK4 serine/threonine kinase function, the ligand is an antibody capable of binding to the PAK4 serine/threonine kinase. In another embodiment of these methods the antibody is a monoclonal or a polyclonal antibody.

35

This invention provides a method of inhibiting growth of a tumor cell comprising blocking Cdc42Hs by administering a ligand capable of binding to a Cdc42Hs binding site of a

-24-

PAK4 serine/threonine kinase. In an embodiment of the method, the tumor cell growth is inhibited in vivo or in vitro. In another embodiment of these methods the ligand is an antibody capable of binding to the PAK4  
5 serine/threonine kinase. In a further embodiment of these methods the antibody is a monoclonal or a polyclonal antibody.

This invention provides a pharmaceutical composition  
10 comprising an amount of any of the above-described ligands, including, but not limited to any of following oligonucleotides: an oligonucleotide comprising a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a unique sequence included  
15 within the sequence of the isolated nucleic acid molecule encoding a mammalian PAK4 serine/threonine kinase, said oligonucleotide being DNA or RNA; an antisense oligonucleotide comprising a sequence capable of specifically hybridizing with a unique sequence included  
20 within the mRNA molecule encoding a mammalian PAK4 serine/threonine kinase; or an antisense oligonucleotide comprising a sequence capable of specifically hybridizing with a unique sequence included within the genomic DNA molecule encoding a mammalian PAK4 serine/threonine kinase,  
25 effective to prevent overexpression of a PAK4 serine/threonine kinase and a pharmaceutically acceptable carrier capable of passing through a cell membrane.

This invention provides a pharmaceutical composition  
30 comprising an amount of any of the following antibodies: an antibody capable of binding to the PAK4 serine/threonine kinase which may be a purified mammalian PAK4 serine/threonine kinase or a purified human PAK4 serine/threonine kinase; said antibody being a monoclonal  
35 antibody or a polyclonal antibody; or a monoclonal antibody directed to an epitope of a PAK4 serine/threonine kinase effective to block binding of a PAK4 serine/threonine kinase to a GTP binding protein and a pharmaceutically

-25-

acceptable carrier capable of passing through a cell membrane.

5 This invention provides a method of treating an abnormality in a subject, wherein the abnormality is alleviated by the inhibition of binding of a PAK4 serine/threonine kinase and a GTP binding protein which comprises administering to the subject an effective amount of any of the above-described pharmaceutical compositions effective to prevent  
10 overexpression of a PAK4 serine/threonine kinase, thereby treating the abnormality in the subject. In an embodiment, the GTP binding protein is Cdc42Hs or Rac. In an embodiment, the abnormality is cancer or arthritis.

15 This invention provides a method of treating an abnormality in a subject, wherein the abnormality is alleviated by the inhibition of binding of a PAK4 serine/threonine kinase and a GTP binding protein which comprises administering to the subject an effective amount of the pharmaceutical  
20 composition comprising any of the above-described antibodies effective to block binding of the PAK4 serine/threonine kinase and the GTP binding protein in the subject, thereby treating the abnormality in the subject. In an embodiment, the GTP binding protein is Cdc42Hs or  
25 Rac. In an embodiment, the abnormality is cancer or arthritis.

This invention provides a method of administering the above-described pharmaceutical composition comprising an  
30 amount of any of the above-described ligands, oligonucleotides or antibodies which are determined to be potentially therapeutic, wherein the administration is intravenous, intraperitoneal, intrathecal, intralymphatic, intramuscular, intralesional, parenteral,  
35 epidural, subcutaneous; by infusion, liposome-mediated delivery, aerosol delivery; topical, oral, nasal, anal, ocular or otic delivery.

-26-

The present invention also provides a pharmaceutical composition comprising a effective amount of any of the above-described ligands, oligonucleotides or antibodies which are determined to be potentially therapeutic and a pharmaceutically acceptable carrier. In the subject invention an "effective amount" is any amount of the above-described ligands, oligonucleotides or antibodies which are determined to be potentially therapeutic, which, when administered to a subject suffering from a disease or abnormality against which the above-described ligands, oligonucleotides or antibodies which are determined to be potentially therapeutic, are effective, causes reduction, remission, or regression of the disease or abnormality. In the practice of this invention the "pharmaceutically acceptable carrier" is any physiological carrier known to those of ordinary skill in the art useful in formulating pharmaceutical compositions.

In one preferred embodiment the pharmaceutical carrier may be a liquid and the pharmaceutical composition would be in the form of a solution. In another equally preferred embodiment, the pharmaceutically acceptable carrier is a solid and the composition is in the form of a powder or tablet. In a further embodiment, the pharmaceutical carrier is a gel and the composition is in the form of a suppository or cream. In a further embodiment the compound may be formulated as a part of a pharmaceutically acceptable transdermal patch.

A solid carrier can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and

-27-

compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, polyvinylpyrrolidone, low melting waxes and ion exchange resins.

Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. The active ingredient can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmoregulators. Suitable examples of liquid carriers for oral and parenteral administration include water (partially containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are useful in sterile liquid form compositions for parenteral administration. The liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellant.

Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by for example, intramuscular, intrathecal, epidural, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. The compounds may be prepared

-28-

as a sterile solid composition which may be dissolved or suspended at the time of administration using sterile water, saline, or other appropriate sterile injectable medium. Carriers are intended to include necessary and inert binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, dyes, and coatings.

The above-described ligands, oligonucleotides or antibodies which are determined to be potentially therapeutic can be administered orally in the form of a sterile solution or suspension containing other solutes or suspending agents, for example, enough saline or glucose to make the solution isotonic, bile salts, acacia, gelatin, sorbitan monoleate, polysorbate 80 (oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide) and the like.

The above-described ligands, oligonucleotides or antibodies which are determined to be potentially therapeutic can also be administered orally either in liquid or solid composition form. Compositions suitable for oral administration include solid forms, such as pills, capsules, granules, tablets, and powders, and liquid forms, such as solutions, syrups, elixirs, and suspensions. Forms useful for parenteral administration include sterile solutions, emulsions, and suspensions.

Optimal dosages to be administered may be determined by those skilled in the art, and will vary with the particular ligands, oligonucleotides or antibodies in use, the strength of the preparation, the mode of administration, and the advancement of the disease condition or abnormality. Additional factors depending on the particular subject being treated will result in a need to adjust dosages, including subject age, weight, gender, diet, and time of administration.

This invention will be better understood from the Experimental Details which follow. However, one skilled in

-29-

the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter.

5

## EXPERIMENTAL DETAILS

### First Series of Experiments

10

## MATERIALS AND METHODS

### Isolation of PAK4

To isolate PAK4, a pair of degenerate oligonucleotide primers were synthesized based on the amino acid sequences conserved among the kinase domains of yeast STE20 and human PAK65. (The two oligos corresponded to the amino acid sequences "KKELIINE" (SEQ ID NO: 11) and "VGTPYWMA", respectively (SEQ ID NO: 12)). The two primers were used to generate a PCR product using Jurkat cell cDNA as a template. Low stringency conditions were used so that diverse products could be obtained. PCR products were gel purified and subcloned. Inserts were sequenced using the dideoxy chain termination method. A 400 bp PCR product containing significant homology to the catalytic domain of STE20 was used as a probe to screen both a human Jurkat cell cDNA library (in the ZAP Express<sup>TM</sup> EcoRI vector) and a human fetal brain cDNA library (in  $\lambda$ TripleX<sup>TM</sup> vector). Nylon transfer filters containing  $1 \times 10^6$  recombinant plaques were hybridized with the randomly primed [ $\alpha$ -<sup>32</sup>P] dCTP-labeled probe (Prime-It II kit, Stratagene) overnight at 42°C in 6xSSC, 50% formamide, 0.1% SDS, and washed at 65°C in 2xSSC, 0.1% SDS according to standard protocol. Positive plaques ( $\approx 40$ ) were taken through further purification and excised in vivo as plasmids. The positive inserts were sequenced on both strands. 5' RACE was carried out to determine that the sequence upstream to the start codon contains an in frame stop codon.

-30-

**Cell Culture and Transfection**

All cells lines were grown at 37°C in 5% CO<sub>2</sub> and cultured in Dulbecco's modified Eagle's medium (DMEM) media containing appropriate serum (HeLa, 10% fetal bovine serum (FBS); NIH3T3, 10% bovine calf serum (BCS); COS-1, 10% newborn calf serum (NCS)). All media were supplemented with 100 units/ml penicillin, 100 (μ/ml streptomycin, and 1 mM glutamate. Transient transfection assays were carried out using the lipofectamine (GIBCO BRL) method according to the manufacturer protocol.

**Protein Kinase Assays**

To assay kinase activity of PAK4, NIH3T3 cells were transfected with either empty Sra expression vector or expression vectors containing HA tagged PAK4. Cells were harvested in M2 buffer (Minden et al., 1994) 48 h after transfection. Approximately 100 μg of cell extracts were mixed with anti-HA antibody and protein A sepharose and incubated 2 h to overnight at 4°C rotating. The immune complexes were washed two times with M2 buffer and two times in 20 mM HEPES, pH 7.5 and incubated in kinase buffer (described in (Minden et al., 1994)) containing, 20 μM ATP and 5 μCi of [γ-<sup>32</sup>P]ATP either alone or together with 5 μg Histone H4 (Boehringer Mannheim) or no substrate, at 30°C for 20 min. The reaction was stopped by boiling in 4xSDS loading buffer. Proteins were resolved by SDS-polyacrylamide gel electrophoresis (PAGE), and substrate phosphorylation and autophosphorylation were visualized by autoradiography. JNK, ERK, and p38 activity were measured as described (Minden et al., 1995).

**Northern Blots**

The Northern analysis was performed using a human tissue blot (Clontech). Hybridization and washes were carried out as recommended by the manufacturer. The probe was prepared by labeling a 400 bp cDNA fragment corresponding to the kinase domain of PAK4 with [α-<sup>32</sup>-P] dCTP (Amersham International PLC) by random priming (Stratagene).

-31-

**Overlay Assay**

The overlay assay is described in Martin et al., 1995. Recombinant and immunopurified proteins were separated on SDS-PAGE followed by blotting to a PVDF membrane, washing, and blocking with PBS containing 1% BSA and 100 mM DTT. Recombinant GTPases (2-5  $\mu$ g) were preloaded with the indicated radiolabeled nucleotide and were incubated for 5-8 min. with the PVDF filter. The filter was washed for 5 min. and was exposed to a film for 2 hours. Recombinant proteins were expressed and purified from Sf9 cells as previously described (Martin et al. 1995). Various Cdc42Hs effector mutants were prepared in *E. coli* as GST fusion proteins and were purified on a glutathione sepharose beads and eluted from the beads by 5 mM reduced glutathione.

**Western Blot**

25  $\mu$ g of COS-1 cell lysates were resolved by SDS-PAGE and transferred to PVDF membrane. The membrane was blocked in PBS containing 0.2% Tween-20 (PBST) and 4% non-fat milk for 1 h and then incubated with anti HA antibody diluted in PBST containing 4% non-fat milk for 1 h. After washing 3 times with PBS, the membrane was probed with secondary antibody, peroxidase-conjugated goat IGG fraction to mouse IGG for 1 h. After washing 3 times with PBS, the immunocomplexes were visualized by enhanced chemiluminescence (ECL) reagent ECL (Amersham Corp.).

**Microinjections and immunofluorescence microscopy**

Microinjections and immunofluorescence microscopy was carried out essentially as described (Symons et al., 1996). Briefly, PAE cells were grown in DMEM medium containing 10% fetal bovine serum and were plated on a coverslip. Expression vectors encoding various PAK4, PAK2, Cdc42Hs and Rac mutants diluted to a concentration of 50 ng/ $\mu$ l in injection buffer (5 mM glutamate, 130 mM KCL), were microinjected into the nucleus of ~ 100 of sub-confluent PAE cells. Injected cells were incubated for 16-20 hr. at

-32-

37°C and fixed in 4% formaldehyde. Cells were permeabilized with PBS containing 0.1% Triton x-100 and incubated in the presence of the primary monoclonal antibodies anti HA or anti Myc for 60 min. The coverslips were washed with PBS containing 0.1% Triton x-100 and was incubated for 30 min. with the second antibody Texas Red conjugated anti mouse antibody. To visualized F-actin, cells were washed again and were incubated with FITC conjugated phalloidin. Fluorescence photomicroscopy was carried out on a Zeiss Axiophot with appropriate filters for fluorescence detection.

#### Preparation of recombinant proteins.

To prepare recombinant PAK4, a BamHI/NOTI fragment containing the full length PAK4 was subcloned into the pAcO-3 baculovirus expression vector containing a 5' Glu-Glu tag. Recombinant protein was then prepared and purified as described in (Martin et al. 1995). Recombinant PAK2 was generated as described in (Martin et al. 1995).

#### Plasmids

To construct HA tagged PAK4, an EcoRI fragment of the cDNA was ligated in frame into the EcoRI site of Bluescript II KS(+) vector containing a 5' HA tag. HA-PAK4 was then removed from Bluescript II KS(+) as a HindIII/StuI fragment and subcloned into HindIII/SmaI site of expression vector SR $\alpha$ 3 (Takebe et al., 1988). PAK4(M350), PAK4(M474), and PAK4(E474) were generated by site directed mutagenesis (Stratagene QuickChange kit) of K(350) or S(474) to methionine or Aspartate. Rac2L61, JNK, p38, ERK and ERK are described in Minden et al., 1995.

#### RESULTS

##### Identification of PAK4, a novel member of the PAK family

To identify new PAK related proteins, degenerate primers were designed corresponding to regions of homology between the kinase domains of yeast STE20 and mammalian hPAK2.

-33-

These primers were used to generate PCR products from Jurkat cell cDNA. The PCR products were subsequently sub-cloned and sequenced, and sequence homologies were obtained by Blast searches of the Gene Bank. Using this technique, partial sequences were identified for several novel putative protein kinases. One of the partial cDNAs was used as a probe to screen Jurkat cell and fetal brain cDNA libraries as described in materials and methods. Two identical clones that hybridize with this cDNA were isolated. One of the clones contained a complete open reading frame of approximately 1.7 KB as shown in Figures 1A-1B. Like the PAK family of kinases, the carboxyl terminal portion of the predicted protein sequence contains the 11 sub-domains that are characteristic of serine/threonine protein kinases. Blast searches of the Gene Bank confirmed that this region is most similar to the kinase domain of human PAK2. This putative kinase domain has 53% identity and 73% similarity with PAK2, and 49% identity and 71% similarity with yeast STE20 (Figure 1C). The amino terminal putative regulatory domain of PAK4 does not share homology with any other known proteins except for a short sequence resembling a modified GBD/CRIB domain. This conserved sequence of approximately 16 amino acids is found in many proteins that bind Rac and Cdc42Hs (Burbelo et al., 1995). This sequence has been shown to be essential and necessary for interactions of these proteins with the GTPases (Burbelo et al., 1995). The GBD/CRIB domain found on PAK4 in comparison with those found on several other Cdc42Hs/Rac binding proteins is shown in Figure 1D. To determine the expression profile of PAK4, a Northern blot was probed with a cDNA probe that corresponds to the kinase domain of PAK4. A band of approximately 3 KB was seen in all of the human tissues that were analyzed. PAK4 appears to be most highly expressed in prostate, testis, and colon (Figure 1E). A band of the same size was detected when the Northern blot was probed with a cDNA corresponding to the PAK4 regulatory domain (not shown).

-34-

**PAK4 interacts with GTP bound form of Cdc42Hs**

The finding that PAK4 has a putative GBD/CRIB motif suggests that it is a new target for Cdc42Hs and/or Rac. An overlay assay was used to determine whether PAK4 interacts with either of these GTP binding proteins. It was found that PAK4 interacts tightly with the GTP bound form of Cdc42Hs and not with the inactive GDP bound form of Cdc42Hs. A much weaker interaction was detected with the GTP bound form of Rac, and no binding was observed with Rho. In contrast, PAK2 interacts with similar affinity to the GTP bound forms of either Rac or Cdc42Hs (Figure 2A). PAK4 lacking the GBD/CRIB domain (PAK4DGBD) does not bind to Cdc42Hs, indicating that the GBD/CRIB domain is required for binding (Figure 2B).

**PAK4 autophosphorylates and phosphorylates an exogenous substrate**

The analysis of PAK4's kinase activity has revealed that it behaves similarly to other serine/threonine kinases. NIH3T3 cells were transfected with either wild-type PAK4 or various mutants of PAK4. PAK4 was immunopurified from cell lysates and incubated in kinase buffer with  $\gamma$ -<sup>32</sup>P-ATP in the presence or absence of the substrate Histone H4. Substrate phosphorylation and autophosphorylation were analyzed after SDS-PAGE and autoradiography. The presence of a band of the exact same size as PAK4 strongly suggests that, like the other PAKs, PAK4 can autophosphorylate (Figure 3A). PAK4 also co-immunopurified with a 42 kDa protein that became phosphorylated in the kinase assay, suggesting that it may be a substrate for PAK4 (Figure 3A). Immunopurified PAK4 was also able to phosphorylate an exogenous substrate, Histone H4 (Figure 3B). The activity of a PAK4(M350) mutant was also tested. This mutant contains a mutation in which the conserved lysine in subdomain II is converted to a non-phosphorylatable residue, methionine. Mutation of this conserved lysine disrupts the ATP binding site of nearly all serine/threonine kinases that have been analyzed (Hanks et al., 1988). Immunopurified PAK4(M350) was

-35-

completely unable to autophosphorylate or, as shown in Figure 3B, to phosphorylate Histone H4. Most serine/threonine kinases contain a conserved serine or threonine residue within the linker region between kinase subdomains VII and VIII. This residue usually becomes phosphorylated either by autophosphorylation or by an upstream kinase. Phosphorylation of this residue is essential for the activities of most serine/threonine kinases (Johnson et al., 1996; Marshall, 1994; Pelech, 1996; Zhang et al., 1994). Consistent with this, mutation of the corresponding serine in PAK4 to a methionine results in a completely inactive PAK4(M474) (Figure 3B). Many protein kinases become further activated when the regulatory domain is removed. PAK4D which contains only the kinase domain was generated. PAK4D exhibits at least 5 fold more kinase activity than wild-type PAK4, suggesting that the carboxyl terminal portion of PAK4 contains a regulatory domain (Figure 3B). Like the wild-type protein however, mutation of the lysine in subdomain II to generate PAK4D(M350) results in a completely inactive kinase (Figure 3B).

#### **PAK4 activates the JNK pathway**

One of the functions of Cdc42Hs and Rac is to activate the JNK and p38 MAP Kinase pathways (Bagrodia et al., 1995; Brown et al., 1996; Coso et al., 1995; Minden et al., 1995; Zhang et al., 1995). Since PAK4 is a target for Cdc42Hs, its ability to activate mammalian MAP Kinase pathways was tested. NIH3T3 cells were transfected with increasing doses of an expression vector containing the PAK4 cDNA. These were co-transfected with expression vectors containing epitope tagged JNK, ERK, or p38 cDNAs. After transient expression, JNK, ERK, or p38 were immunopurified from cell lysates using antibodies against the epitope tag, followed by an *in vitro* kinase assay. The results indicate that overexpression of the wild-type PAK4 leads to activation of the JNK pathway, although this activation is somewhat weak compared with other JNK activators such as Rac or Cdc42Hs

-36-

(Figure 3C). PAK4 has little activity towards ERK, and does not activate the p38 pathway (Figure 3D and E).

**PAK4 induces localized actin polymerization and induces the formation of filopodia**

Since PAK4 is a novel target for Cdc42Hs, its role in the induction of cytoskeletal changes was studied. Microinjection of fibroblasts with purified constitutively active Cdc42HsV12 protein has been shown to lead to a transient induction of filopodia (Kozma et al., 1995; Nobes and Hall, 1995). The filopodia disappear within a short time (by 15-30 minutes) after microinjection of the protein followed by the formation of lamellipodia, due to the ability of Cdc42Hs to activate Rac (Kozma et al., 1995; Nobes and Hall, 1995). Another consequence of Cdc42Hs microinjection is the dissolution of stress fibers. To see whether PAK4 can potentiate the cytoskeletal effects triggered by the GTPases, PAE cells were microinjected with expression vectors for HA tagged PAK4 either alone or together with myc tagged Cdc42HsV12 or Rac1V12 expression vectors (Symons et al., 1996). The experiments described herein were also carried out with NIH3T3 fibroblasts, with similar results. As shown in Figures 4A-4F, when expressed alone, PAK4 was localized in a perinuclear area and did not affect the actin cytoskeleton. Cells microinjected with expression vectors for constitutively active Rac1V12 or Cdc42HsV12 alone induced extensive lamellipodia. Filopodia were not observed in the Cdc42Hs injected cells because cells were analyzed between 12-16 hours after microinjection. Interestingly, co-expression of PAK4 with Cdc42HsV12 caused dramatic changes in the actin cytoskeleton and re-distribution of PAK4. When co-injected with Cdc42HsV12, PAK4 became concentrated in one side of the nucleus in an area that resembles the trans Golgi compartment (Figures 4A-4F). Dual staining with phalloidin and HA antibody revealed a striking co-localization of PAK4 with polymerized actin clusters (Figures 4A-4F), and in cells expressing lower levels of PAK4, polymerized actin

-37-

was detected around vesicles (data not shown). In addition, co-expression of PAK4 and Cdc42HsV12 induced the sustained formation of actin enriched filopodia protrusions in more than 70% of the injected cells and also caused the dis-assembly of stress fibers (Figures 4A-4F). Co-expression of PAK4 with a dominant negative Cdc42HsN17 had no effect on PAK4 localization or the reorganization of the actin cytoskeleton (data not shown). Co-expression of PAK4 and the constitutively active Rac1V12 resulted in a very similar phenotype to that observed with Rac1V12 alone. Rac1V12 induced the formation of lamellipodia and relocalization of a small percentage of PAK4 from the perinuclear area to the lamellipodia (Figures 4A-4F). To test whether these phenotypes are specific for PAK4, PAK2 expression vector with either Rac1V12 or Cdc42HsV12 expression vector was co-injected. PAK2 was localized in the cytosol and the nucleus and was not redistributed by Rac or Cdc42Hs (data not shown). In addition, cells co-expressing Rac1V12 or Cdc42HsV12 together with PAK2 had similar cytoskeletal phenotypes as cells expressing Rac1V12 or Cdc42Hs alone (Figure 4G-4J). This data strongly suggests that in contrast to PAK2, PAK4 is the effector for Cdc42Hs that leads to the induction of filopodia and actin polymerization.

25

**PAK4 is recruited to the Golgi apparatus by activated Cdc42Hs**

PAK4 appears to be regulated by specific recruitment by Cdc42Hs to an area resembling the trans-Golgi. It is interesting to note that the endogenous Cdc42Hs was recently shown to be localized primarily at Golgi membranes, and to localize with the Golgi membrane coatomer protein b-COP (Erickson et al., 1996). In addition, a recently identified Cdc42Hs related protein was also localized to the Golgi structure (unpublished observation). To determine whether PAK4 also localizes to the Golgi, injected cells were co-stained with anti HA and anti b-COP antibody. As presented in Figures 5A-5H, in cells

-38-

expressing PAK4 alone, PAK4 was localized to perinuclear areas and was not co-localized with b-COP. In cells co-expressing PAK4 and Cdc42HsV12 however, PAK4 was co-localized with b-COP in the Golgi.

5

The effects of the drug Brefeldin A (BFA) on PAK4 location were tested. Golgi coatomer proteins are normally redistributed when cells are exposed to BFA (Orci et al., 1991). Likewise, Cdc42Hs is redistributed from its Golgi location when cells are treated with BFA (Erickson et al., 1996). Interestingly, treatment of injected cells with BFA was found to also cause a rapid redistribution of PAK4 from the Golgi to the cytoplasm and the nucleus. This is nearly identical to the effects of BFA on b-COP in these cells (Figures 5A-5H). This data strongly suggests that in the presence of Cdc42Hs, PAK4 is localized at a BFA sensitive component of Golgi membranes. In addition, BFA treated cells contained less filopodia and polymerized actin. This data suggests that the localization of PAK4 by Cdc42Hs to the Golgi may play an important role in the reorganization of actin.

20

**PAK4 kinase activity is required for its ability to induce localized actin polymerization and to potentiate filopodia formation by Cdc42Hs**

25

The effect of PAK4 mutants on the formation of filopodia and actin polymerization was tested. The kinase inactive PAK4(M350) was microinjected into cells either alone or together with Cdc42HsV12. Like PAK4 wt, PAK4(M350) was localized in the perinuclear area and was recruited by Cdc42Hs to the BFA sensitive compartment of the Golgi (Figures 6A-6H). However, in contrast to PAK4 wt, PAK4(M350) was unable to induce localized actin polymerization or the formation of filopodia, and did not lead to a reduction in stress fibers (Figures 6A-6H). A putative constitutively active PAK4 mutant was also generated. This mutant was generated by mutation of serine 474 (in the linker region between subdomains VII and VIII)

30

35

-39-

to a glutamic acid. The resulting PAK(E474) mutant had a greatly enhanced autophosphorylation activity (data not shown). Mutation of this conserved site to a negatively charged amino acid has been found to generate constitutively active mutants of many serine/threonine kinases including the PAKs (Benner et al., 1995; Manser et al., 1997; Szczepanowska et al., 1997). When expressed alone, PAK4(E474) localized to similar areas as PAK4 wt and PAK4(M350), and did not have any effect on the actin cytoskeleton. Like PAK4 wt, PAK4(E474) was recruited specifically by Cdc42HsV12 to the Golgi and induced the formation of filopodia and polymerization of actin to the same extent as wild-type PAK4 (Figures 6A-6H). Taken together, these data indicate that PAK4's kinase activity is not necessary for the cellular localization of PAK4, but is essential for its effects on actin polymerization. The kinase activity of wild-type PAK4 appears to be sufficient to induce the cytoskeletal changes however, as the PAK4(E474) mutant had no enhanced effect on actin polymerization and filopodia formation. Furthermore, unlike results described for PAK1, constitutively active PAK4 did not induce cytoskeletal changes on its own, but maintained the requirement for recruitment by Cdc42Hs to the golgi.

#### **PAK4 binds Cdc42Hs effector mutants to induce filopodia and actin polymerization**

Two effector mutants of constitutively active Cdc42HsL61 were previously examined to assess the role of PAK and other effectors in filopodia formation (Lamarche et al., 1996). Both mutants had single amino acid substitutions in the effector loop. One mutant, Cdc42HsL61(Y40C) could not bind PAK or several other GBD/CRIB domain containing proteins. The other mutant, Cdc42HsL61(F37A), maintained the ability to bind PAK and other GBD/CRIB domain containing proteins. Interestingly, both effector mutants were equally efficient in the ability to induce filopodia when microinjected into fibroblasts together with dominant negative Rac (Lamarche et al., 1996). These results would

-40-

tend to suggest that PAK binding to Cdc42Hs is not necessary for filopodia formation. To see whether Cdc42HsL61(Y40C) could be mediating its effects through PAK4, PAK4 binding to Cdc42HsL61 and to the two effector mutants was tested. For comparison PAK2 and another GBD/CRIB containing protein, WASP (Symons et al., 1996) were also analyzed. As shown in Figure 7A, all three proteins bound to Cdc42HsL61. Likewise, as expected, they also all bound to Cdc42Hs(F37A), though with a slightly lower affinity. Surprisingly however, PAK4 bound Cdc42HsL61(Y40C) with a similar affinity as was detected with Cdc42HsL61(F37A), although WASP and PAK2 did not bind Cdc42HsL61(Y40C) efficiently. Moreover, when Cdc42HsL61(C40) was co-injected into PAE cells with PAK4, PAK4 was recruited to the Golgi area, induced actin polymerization, and promoted the formation of filopodia (see Figures 7B-7C). The results suggest a mechanism whereby the effector mutant Cdc42HsL61(Y40C) can induce filopodia formation. Although it can not efficiently bind PAK2, this mutant maintains the ability to interact with PAK4. Importantly, it was found that PAK4, rather than the other known PAKs, is the important mediator of filopodia formation by Cdc42Hs.

## DISCUSSION

PAK4 was identified as a novel member of the PAK family. Like the other PAKs, PAK4 contains a GBD/CRIB domain at the N-terminus and a kinase domain at the C-terminus. The overall sequence identity to other PAKs, however, is significantly different. Although the kinase domain of PAK4 is more similar in sequence to the kinase domains of PAK 1, 2, and 3 than to any other known proteins, it shares only 53% sequence identity. PAK4 exhibits no sequence homology in the regulatory domain outside the GBD/CRIB sequences. Even the GBD/CRIB motif is similar, but not identical, to the GBD/CRIB motif in the other PAKs. This suggests that PAK4 may have a different function than the

-41-

known PAKs. It was shown that PAK4 interacts preferentially with the GTP bound form of Cdc42Hs and activates the JNK family of MAP Kinases. Moreover, microinjection of PAK4 and Cdc42Hs plasmids into different cell types demonstrates that PAK4 has a profound effect on the actin cytoskeleton. When co-injected with Cdc42Hs, PAK4 is recruited by Cdc42Hs to the brefeldin A sensitive compartment of the Golgi, and subsequently induces actin polymerization at the Golgi. Strikingly, PAK4 also greatly stimulates the induction of filopodia when it is co-injected with Cdc42Hs. In contrast to other PAKs, PAK4 kinase activity and its interaction with the activated Cdc42Hs are essential for the induction of this phenotype. In addition, PAK4 interacts with the Cdc42Hs effector mutant (Cdc42L61(C40)) which was previously shown to be important in the induction of filopodia but which failed to bind other PAKs (Lamarche et al., 1996). The data provides a novel link between Cdc42Hs, PAK4, and actin polymerization, and supports the idea that the Golgi apparatus plays a role in cytoskeletal re-organization.

The Rho family of GTPases play key roles in the control of cell morphology. By using microinjection techniques it was demonstrated that Cdc42Hs triggers the formation of microspikes and filopodia followed by activation of Rac, which leads to the formation of lamellipodia. A third GTPase, RhoA, is implicated in the formation of stress fibers. In addition, all three GTPases regulate the assembly of focal complexes. The cytoskeletal changes triggered by these GTPases play important roles in cell motility and division and in the maintenance of cell shape. The identification of molecular targets which mediate these cytoskeletal effects is therefore of great importance. Several proteins were shown to interact with the activated form of Cdc42Hs, however, the molecular effector that links Cdc42Hs to the formation of filopodia has not yet been identified. Recent experiments with various effector mutants of Cdc42Hs demonstrated that the cytoskeletal

changes induced by Cdc42Hs are independent of PAK1, 2 or 3. In this report it has been shown that a novel PAK related protein, PAK4, interacts only with the GTP bound form of Cdc42Hs and not with other Rho members. The interaction  
5 between Cdc42Hs and PAK4 is essential for targeting PAK4 to the Golgi compartment and subsequently for the re-organization of the actin cytoskeleton. In contrast to PAK1, 2, and 3, the kinase activity of PAK4 is not regulated by Cdc42Hs (data not shown). Thus, it appears to  
10 be recruitment of PAK4 by Cdc42Hs, rather than stimulation of its kinase activity, which is important for actin polymerization and cytoskeletal changes. PAK4's kinase activity is necessary however, because a kinase inactive PAK4 mutant was re-localized to the Golgi by Cdc42Hs, but  
15 failed to reorganize the actin cytoskeleton. In addition to kinase activity, localization by Cdc42Hs is critical for PAK4 to induce actin polymerization and filopodia formation. Even a constitutively active PAK4 could not bypass the need for recruitment by Cdc42Hs to the Golgi.  
20 This mutant localized to the same area in the cell as wild-type PAK4, and only when it was recruited to the Golgi compartment by Cdc42Hs did induce the formation of filopodia and actin polymerization. These experiments strongly suggest that PAK4 mediates its biological effect  
25 by translocation to a specific site by Cdc42Hs and thereby bringing PAK4 to close proximity with a putative substrate.

This mechanism of activation of PAK4 is substantially  
30 different than the one proposed for other PAK members. PAK 1 was shown to be recruited to the focal complexes induced by Cdc42Hs, but the recruitment to these sites did not require a direct interaction with Cdc42Hs. Recently, it was demonstrated that PAK1 is recruited to the focal  
35 complexes by interacting with a novel GTP/GDP exchange factor PIX. A specific proline rich sequence on the PAK regulatory domain interacts with the SH3 domain of PIX. Furthermore, it was proposed that the PAK/PIX complex

-43-

activates the Rac signaling pathways. Interestingly, PAK kinase activity was not required for activation of the Rac pathway, but was shown to be important in the disassembly of the focal complexes. PAK1 has also been reported to induce filopodia and lamellipodia similar to those induced by Cdc42Hs and Rac. However, these cytoskeletal changes occur independently of PAK1's ability to bind Cdc42Hs and Rac, and are partly independent of its kinase activity. These results, coupled with the results from experiments using effector mutants of Rac and Cdc42Hs suggest that, while PAK1 may be able to induce cytoskeletal changes when it is overexpressed, it might not be the link between GTPases and the cytoskeleton.

Recent studies indicated that Cdc42Hs is localized to the BFA sensitive compartment of the Golgi apparatus. The role of Cdc42Hs in the Golgi is poorly understood. The Golgi apparatus is known mostly for its roles in the formation of transport vesicles which carry cargo to a receiving compartment. Nonclathrin coat proteins such as bCOP and the GTPase ARF were shown to be implicated in Golgi mediated transport. Disruption of the coatomer complexes by treating cells with BFA or expressing dominant negative forms of ARF blocked the transport of vesicles to the plasma membrane. These data indicated that PAK4 is co-localized with bCOP and is redistributed by treating the cells with BFA. Furthermore, BFA treatment affected the filopodia formation and actin polymerization induced by PAK4 and Cdc42HsV12. Interestingly, it was previously reported that fibroblast treated with BFA failed to make filopodia and lamellipodia and subsequently cells were defective in motility. It has been proposed that the disruption of the Golgi apparatus by BFA may affect the supply of vesicles containing the components necessary for the formation of filopodia. Because it is localized by Cdc42Hs to the Golgi, PAK4 is a good candidate for an effector molecule that transduces a Cdc42Hs dependent signal from the Golgi. It is conceivable that PAK4 and

-44-

Cdc42Hs regulate the re-organization of actin and the formation of filopodia by controlling the transport of vesicles containing the proteins and/or lipids necessary for the induction of morphological changes. Interestingly, in addition to the induction of filopodia, PAK4 also leads to localized actin polymerization at the Golgi area. In future studies it will be interesting to determine whether actin polymerization in this area is important for vesicle fusion or other aspects of Golgi function.

In summary, PAK4 provides a molecular link between Cdc42Hs and actin rearrangement, and suggests involvement of the Golgi apparatus in cell morphogenesis. Understanding how PAK4 together with Cdc42Hs and putative targets at the Golgi control the reorganization of the actin cytoskeleton will contribute to the understanding of the molecular mechanism of morphogenesis.

#### Second Series of Experiments

##### **Mouse PAK4 sequences:**

1) Partial cDNA of the mouse PAK4:

AAGCAGCAGC GGC GCGAGTT GCTCTTCAAT GAGGTGGTGA TCATGCGGGA  
CTACCGGCAC GAGAACGTGG TGGAGATGTA CAACAGCTAC CTGGTGGGTT  
ACGAACTCTG GGTCGTCATG GAGTTCCTGG AAGGCGGCGC CCTCACGGAT  
ATTGTCACCC ACACCAGGAT GAACGAGGAA CAGATCGCCG CCGTGTGCCT  
GGCTGTGCTT CAGGCGCTGG CTGTGCTCCA CGCCCAGGGT GTCATCCACA  
GCGACATAAA AACGGACA (SEQ ID NO: 13)

2) predicted amino acid sequence of the partial mouse PAK4 cDNA:

KQQRRELLFN EVVIMRDYRH ENVVEMYSY LVGDELWVVM EFLEGGALTD  
IVTHTRMNEE QIAAVCLAVL QALAVLHAQG VIHSDIKTD (SEQ ID NO: 14)

3) Partial genomic sequence of mouse PAK4:

-45-

ACCTGGTGGG TGACGAACTC TGGGTCGTCA TGGAGTTCCT GGAAGGCGGC  
GCCCTCACGG ATATTGTCAC CCACACCAGG TACCATAGGG CAGCCTGCTG  
GCTCATGTGC TCCCTGGGGT GGAAGTGGGA CCCTTTAGGC TCTGGTGATA  
5 GACAAGTGCC CTCCAGAGTG TGGGTGGGGC AGTGAGGCCA GGCACACAGG  
ATGGGGGTCA TAGCATCGTG GCTCCCTGAC CCCTGTTGAG GCGGGTCTTT  
GTGACCTCTT GTTGTCTAAA GCAGGGTAGG GGCCTCTTCA CTGCCCACTC  
TCACCCAGG GTGGGATGCC CAAGGCAGCG CTGAGTGCCC AGTTGCTCCT  
CTGCCCAGCG AGGATGAACG AGGAACAGAT CGCCGCCCGT GTGCTGGCT  
10 TGTGCTTCAN GCGCTGGCTT GTGCTCCACG CCCAGGGTGT CATCCACCGT  
GACATCAAGA GTGACTCTAT CTTGCTGACC CATGATGGC (SEQ ID NO: 15)

## 15 METHODS

### 1) Isolation of the partial mouse cDNA:

The partial mouse cDNA was generated by degenerate PCR using  
degenerate primers corresponding to the following amino acid  
20 sequences: (a) GEGSTG (SEQ ID NO: 16) (b) SLVGTP (SEQ ID NO:  
17) within the kinase domain of PAK4. The degenerate primers  
were used in a PCR reaction using mouse cDNA (from NIH3T3  
cells) as a template

25 2) Isolation of the full length mouse PAK4; The partial cDNA  
is currently being used to isolate the full length PAK4cDNA.  
The partial cDNA will be used as a probe to screen a mouse  
brain cDNA library (Stratagene). Nylon transfer filters  
containing 1x10<sup>6</sup> recombinant plaques will be hybridized with  
30 the randomly primed [ $\alpha$ -<sup>32</sup>P] dCTP-labeled probe (Prime-It II  
kit, Stratagene) overnight at 42°C in 6xSSC, 50% formamide,  
0.1% SDS and washed at 65°C in 2xSSC, 0.1% SDS according to  
standard protocol. Positive plaques will be taken through  
further purification and excised in vivo as plasmids. The  
35 positive inserts will be sequenced in both strands. If  
necessary, 5' RACE and 3' RACE will be carried out to isolate  
the 5' and 3' ends.

-46-

## 3) Isolation of the mouse genomic sequence:

5 The partial mouse cDNA was used as a probe to screen a BAC  
system (Bacterial Artificial Chromosome) mouse genomic library  
(Genome Systems). Positive clones were subcloned into a  
Bluescript vector and analyzed by Southern Blots and  
sequencing. One of the positive clones (8kb) has been  
10 sequenced partially, and found to contain the sequence shown  
above. This clone will be further sequenced to determine  
whether it contains the full length genomic PAK4 sequence, it  
will be used as a probe to undergo a further round of  
screening, until the full length sequence is isolated.

## REFERENCES

- Aspenstrom, P., Lindberg, U., and Hall, A. (1996). Two GTPases, Cdc42 and Rac, bind directly to a protein implicated in the immunodeficiency disorder Wiskott-Aldrich syndrome. Curr Biol 6, 70-75.
- Bagrodia, S., Derijard, B., Davis, R. J., and Cerione, R. A. (1995). Cdc42 and PAK-mediated signaling leads to Jun kinase and p38 mitogen-activated protein kinase activation. J Biol Chem 270, 27995-27998.
- Bashour, A. M., Fullerton, A. T., Hart, M., and Bloom, G. S. (1997). IQGAP1, a Rac- and Cdc42-binding protein, directly binds and cross-links microfilaments. J Cell Biol 137, 1555-1566.
- Benner, G. E., Dennis, P. B., and Masaracchia, R. A. (1995). Activation of an S6/H4 kinase (PAK 65) from human placenta by intramolecular and intermolecular autophosphorylation. J Biol Chem 270, 21121-21128.
- Bershadsky, A., and Futerman, A. (1994). Disruption of the Golgi apparatus by brefeldin A blocks cell polarization and inhibits directed cell migration. Proc Natl Acad Sci U.S.A. 91, 5686-5689.
- Brown, J. L., Stowers, L., Baer, M., Trejo, J., Coughlin, S., and Chant, J. (1996). Human Ste20 homologue hPAK1 links GTPases to the JNK MAP kinase pathway. Curr Biol 6, 598-605.
- Burbelo, P. D., Drechsel, D., and Hall, A. (1995). A conserved binding motif defines numerous candidate target proteins for both Cdc42 and Rac GTPases. J Biol Chem 270, 29071-29074.
- Coso, O. A., Chiariello, M., Yu, J. C., Teramoto, H., Crespo, P., Xu, N., Miki, T., and Gutkind, J. S. (1995). The small

-48-

GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. *Cell* 81, 1137-1146.

5 Cvrckova, F., De Virgilio, C., Manser, E., Pringle, J. R., and Nasmyth, K. (1995). Ste20-like protein kinases are required for normal localization of cell growth and for cytokinesis in budding yeast. *Genes Dev.* 9, 1817-1830.

10 Dascher, C., and Balch, W. E. (1994). Dominant inhibitory mutants of ARF1 block endoplasmic reticulum to Golgi transport and trigger disassembly of the Golgi apparatus. *J Biol Chem* 269, 1437-48.

15 Dharmawardhane, S., Sanders, L. C., Martin, S. S., Daniels, H., and Bokoch, G. M. (1997). Localization of p21-activated kinase 1 (PAK1) to pinocytic vesicles and cortical actin structures in stimulated cells. *J Cell Biol* 138, 1265-1278.

20 Donaldson, J. G., Cassel, D., Kahn, R. A., and Klausner, R. D. (1992). ADP-ribosylation factor, a small GTP-binding protein, is required for binding of the coatamer protein beta-COP to Golgi membranes. *Proc Natl Acad Sci U S A* 89, 6408-12.

25 Donaldson, J. G., Finzaai, D., and Klausner, R. D. (1992). Brefaldin A inhibits golgi membrane-catalysed exchange of guanine nucleotide into ARF protein. *Nature* 360, 350-352.

30 Dutartre, H., Davoust, J., Gorvel, J. P., and Chavrier, P. (1996). Cytokinesis arrest and redistribution of actin-cytoskeleton regulatory components in cells expressing the Rho GTPase CDC42Hs. *J Cell Sci* 109, 367-377.

35 Erickson, J. W., Cerione, R. A., and Hart, M. J. (1997). Identification of an actin cytoskeletal complex that includes IQGAP and the Cdc42 GTPase. *J Biol Chem* 272, 24443.

Erickson, J. W., Zhang, C. j., Kahn, R. A., Evans, T., and

-49-

- Cerione, R. A. (1996). Mammalian Cdc42 is a brefeldin A-sensitive component of the Golgi apparatus. *J Biol Chem* 271, 26850-26854.
- 5     Fukata, M., Kuroda, S., Fujii, K., Nakamura, T., Shoji, I., Matsuura, Y., Okawa, K., Iwamatsu, A., Kikuchi, A., and Kaibuchi, K. (1997). Regulation of cross-linking of actin filament by IQGAP1, a target for Cdc42. *J Biol Chem* 272, 29579-29583.
- 10     Hanks, S. K., Quinn, A. M., and Hunter, T. (1988). The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. *Science* 241, 42-52.
- 15     Hart, M.J., Callow, M.G., Souza, B., Polakis, P. (1996). IQGAP, a colmodulin-binding protein with a rasGAP- related domain, is a potential effector for cdc4Hs. *EMBO J.* 15, 2997-3005.
- 20     Helms, J. B., and Rothman, J. E. (1992). Inhibition by brefeldin A of a golgi membrane enzyme that catalyses exchange of guanine nucleotide bound to ARF. *Nature* 360, 352-354.
- 25     Johnson, L., N. , Noble, M. E., and Owen, D. J. (1996). Active and inactive protein kinases: structural basis for regulation. *Cell* 85, 149-158.
- 30     Joneson, T., McDonough, M., Bar-Sagi, D., and Van Aelst, L. (1996). RAC regulation of actin polymerization and proliferation by a pathway distinct from Jun kinase. *Science* 274, 1374-1376.
- 35     Kozma, R., Ahmed, S., Best, A., and Lim, L. (1995). The Ras-related protein Cdc42Hs and bradykinin promote formation of peripheral actin microspikes and filopodia in Swiss 3T3 fibroblasts. *Mol Cell Biol* 15, 1942-1952.

- Kuroda, S., Fukata, M., Kobayashi, K., Nakafuku, M., Nomura, N., Iwamatsu, A., Kaibuchi, K. (1996). Identification of IQGAP as a putative target for the small GTPases, Cdc42 and Rac1. *J. Bio. chem.* 271, 23363-23367.
- 5 Lamarche, N., Tapon, N., Stowers, L., Burbelo, P. D., Aspenstrom, P., Bridges, T., Chant, J., and Hall, A. (1996). Rac and Cdc42 induce actin polymerization and G1 cell cycle progression independently of p65PAK and the JNK/SAPK MAP
- 10 kinase cascade. *Cell* 87, 519-529.
- Manser, E., Huang, H. Y., Loo, T. H., Chen, X. Q., Dong, J. M., Leung, T., and Lim, L. (1997). Expression of constitutively active alpha-PAK reveals effects of the kinase
- 15 on actin and focal complexes. *Mol Cell Biol* 17, 1129-1143.
- Manser, E., Leung, T., Salihuddin, H., Zhao, Z. S., and Lim, L. (1994). A brain serine/threonine protein kinase activated by Cdc42 and Rac1. *Nature* 367, 40-46.
- 20 Manser, E., Leun, T., Salihuddin, H., Tan, L., and Lim, L. (1993). A non-receptor tyrosine kinase that inhibits the GTPase activity of p21cdc42. *Nature* 363, 364-367.
- 25 Manser, E., Loo, T., Koh, C.-G., Zhao, Z.-S., Chen, X.-Q., Tan, L., Tan, I., Leung, T., and Lim, L. (1998). PAK kinases are directly coupled to the PIX family of nucleotide exchange factors. *Mol Cell* 1, 183-192.
- 30 Marshall, C. J. (1994). Signal transduction. Hot lips and phosphorylation of protein kinases. *Nature* 367, 686.
- Martin, G. A., Bollag, G., McCormick, F., and Abo, A. (1995). A novel serine kinase activated by rac1/CDC42Hs-dependent
- 35 autophosphorylation is related to PAK65 and STE20. *EMBO J* 14, 1970-1978.

-51-

Minden, A., Lin, A., Claret, F. X., Abo, A., and Karin, M. (1995). Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. *Cell* 81, 1147-1157.

5

Minden, A., Lin, A., McMahon, M., Lange-Carter, C., Derijard, B., Davis, R. J., Johnson, G. L., and Karin, M. (1994). Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. *Science* 266, 1719-1723.

10

Nobes, C. D., and Hall, A. (1995). Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. *Cell* 81, 53-62.

15

Orci, L., Tagaya, M., Amherdt, M., Perrelet, A., Donaldson, J. G., Lippincott-Schwartz, J., Klausner, R. D., and Rothman, J. E. (1991). Brefeldin A, a drug that blocks secretion, prevents the assembly of non-clathrin-coated buds on Golgi cisternae. *Cell* 64, 1183-1195.

20

Pelech, S. L. (1996). Kinase connections on the cellular intranet. *Signalling pathways. Curr Biol* 6, 551-554.

25

Rana, A., Gallo, K., Godowski, P., Hirai, S., Ohno, S., Zon, L., Kyriakis, J. M., and Avruch, J. (1996). The mixed lineage kinase SPRK phosphorylates and activates the stress-activated protein kinase activator, SEK-1. *J Biol Chem* 271, 19025-19028.

30

Schekman, R., and Orci, L. (1996). Coat proteins and vesicle budding. *Science* 271, 1526-1533.

35

Sells, M. A., and Chernof, J. (1997). Emerging from the Pak: the p21-activated protein kinase family. *Trends Cell Biol* 7, 162-167.

Sells, M. A., Knaus, U. G., Bagrodia, S., Ambrose, D. M.,

-52-

- Bokoch, G. M., and Chernoff, J. (1997). Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells. *Curr Biol* 7, 202-210.
- 5 Symons, M., Derry, J. M., Karlak, B., Jiang, S., Lemahieu, V., McCormick, F., U., F., and Abo, A. (1996). Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization. *Cell* 84, 723-734.
- 10 Szczepanowska, J., Zhang, X., Herring, C., Qin, J., Korn, E. D., and Brzeska, H. (1997). Identification by mass spectrometry of the phosphorylated residue responsible for activation of the catalytic domain of myosin I heavy chain kinase, a member of the PAK/STE20 family. *Proc Natl Acad Sci*
- 15 *USA* 94, 8503-8508.
- Takebe, Y., Seiki, M., Fujisawa, J., Hoy, P., Yokota, K., Arai, K., Yoshida, M., and Arai, N. (1988). SR alpha promoter: an efficient and versatile mammalian cDNA expression system
- 20 composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. *Mol. Cell. Biol.* 8, 466-472.
- Teramoto, H., Coso, O. A., Miyata, H., Igishi, T., Miki, T.,
- 25 and Gutkind, J. S. (1996). Signaling from the small GTP-binding proteins Rac1 and Cdc42 to the c-Jun N-terminal kinase/stress-activated protein kinase pathway. A role for mixed lineage kinase 3/protein-tyrosine kinase 1, a novel member of the mixed lineage kinase family. *J Biol Chem* 271,
- 30 27225-227228.
- Van Aelst, L., and D'Souza-Schorey, C. (1997). Rho GTPases and signaling networks. *Genes Dev* 11, 2295-2322.
- 35 Van Aelst, L., Joneson, T., and Bar-Sagi, D. (1996). Identification of a novel Rac1-interacting protein involved in membrane ruffling. *EMBO J* 15, 3778-3786.

-53-

Westwick, J. K., Lambert, G. T., Clark, G. J., Symons, M., Van Aelst, L., Pestell, R. G., and Der, C. J. (1997). Rac Regulation of Transformation, Gene Expression, and Actin Organization by Multiple, PAK-Independent Pathways. Mol. Cell. Biol 17, 1324-1335.

Zhang, C. J., Rosenwald, A. G., Willingham, M. C., Skuntz, S., Clark, J., and Kahn, R. A. (1994). Expression of a dominant allele of human ARF1 inhibits membrane traffic in vivo. J Cell Biol 124, 289-300

Zhang, F., Strand, A., Robbins, D., Cobb, M. H., and Goldsmith, E. J. (1994). Atomic structure of the MAP kinase ERK2 at 2.3 Å resolution. Nature 367, 704-711.

Zhang, S., Han, J., Sells, M. A., Chernoff, J., Knaus, U. G., Ulevitch, R. J., and Bokoch, G. M. (1995). Rho family GTPases regulate p38 mitogen-activated protein kinase through the downstream mediator Pak1. J Biol Chem 270, 23934-23936.

-54-

What is claimed is:

1. An isolated mammalian nucleic acid molecule encoding a PAK4 serine/threonine kinase.
2. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is a DNA molecule.
3. The isolated DNA molecule of claim 2, wherein the DNA molecule is a cDNA molecule.
4. The isolated DNA molecule of claim 2, wherein the DNA molecule is a genomic DNA molecule.
5. The isolated nucleic acid of claim 1, wherein the nucleic acid molecule is an RNA molecule.
6. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule encodes a mammalian PAK4 serine/threonine kinase.
7. The isolated nucleic acid molecule of claim 1, wherein the mammalian PAK4 serine/threonine kinase is a human, mouse or rat PAK4 serine/threonine kinase.
8. The isolated nucleic acid molecule of claim 6, wherein the nucleic acid molecule encodes a PAK4 serine/threonine kinase comprising an amino acid sequence as set forth in Figure 1A (SEQ ID NO: 2).
9. The isolated nucleic acid molecule of claim 8, wherein the amino acid sequence comprises a GTPase binding domain (GBD).
10. The isolated nucleic acid molecule of claim 6, wherein the nucleic acid molecule encodes a PAK4 serine/threonine kinase, wherein the PAK4

-55-

serine/threonine kinase has substantially the same amino acid sequence as set forth in Figure 1A (SEQ ID NO: 2).

- 5        11. The isolated nucleic acid molecule of claim 6, wherein the nucleic acid molecule encodes a PAK4 serine/threonine kinase, wherein the PAK4 serine/threonine kinase has the amino acid sequence as set forth in Figure 1A (SEQ ID NO: 2).
- 10       12. An isolated nucleic acid molecule encoding a mutant homolog of the mammalian PAK4 serine/threonine kinase whose amino acid sequence is set forth in Figure 1A (SEQ ID NO: 2).
- 15       13. The isolated nucleic acid molecule of claim 12, which is a deletion mutant.
- 20       14. The deletion mutant of claim 13, wherein the encoded mutant homolog comprises a GTPase binding domain.
15. The deletion mutant of claim 13, wherein the encoded mutant homolog does not comprise a GTPase binding domain.
- 25       16. The isolated nucleic acid molecule of claim 6, wherein the mammalian PAK4 serine/threonine kinase comprises the nucleic acid sequence set forth in Figure 1A (SEQ ID NO:1).
- 30       17. A fusion protein comprising a PAK4 serine/threonine kinase or a fragment thereof and a second peptide.
- 35       18. A vector comprising the nucleic acid molecule of claim 1.
19. The vector of claim 18 adapted for expression in a

-56-

- 5 host cell which comprises the regulatory elements necessary for expression of the nucleic acid molecule in the host cell operatively linked to the nucleic acid molecule encoding the PAK4 serine/threonine kinase as to permit expression of the PAK4 serine/threonine kinase.
- 10 20. The vector of claim 19, wherein the host cell is a eukaryotic, bacterial, insect or yeast cell.
21. The vector of claim 20, wherein the eukaryotic host cell is a mammalian cell.
- 15 22. The vector of claim 21, wherein the vector is a plasmid.
23. A vector comprising the nucleic acid molecule of claim 3.
- 20 24. The vector of claim 23 adapted for expression in a host cell which comprises the regulatory elements necessary for expression of the nucleic acid molecule in the host cell operatively linked to the nucleic acid molecule encoding the PAK4 serine/threonine kinase as to permit expression of the PAK4 serine/threonine kinase.
- 25 25. The vector of claim 24, wherein the host cell is a eukaryotic, bacterial, insect or yeast cell.
- 30 26. The vector of claim 25, wherein the eukaryotic host cell is a mammalian cell.
27. The vector of claim 26, wherein the vector is a plasmid.
- 35 28. The plasmid of claim 27 designated SroHAPAK4 (ATCC Accession No. 209888).

-57-

29. A method of producing a PAK4 serine/threonine kinase, which comprises growing a host cell comprising the vector of claim 24 under suitable conditions permitting production of the PAK4 serine/threonine kinase and recovering the PAK4 serine/threonine kinase so produced.
30. The method of claim 29, further comprising purifying the recovered PAK4 serine/threonine kinase.
31. A method of producing a polypeptide having the biological activity of a protein encoded by the nucleic acid molecule encoding a PAK4 serine/threonine kinase which comprises growing the host cells of claim 24 under suitable conditions permitting production of the polypeptide and recovering the polypeptide so produced.
32. The method of claim 31, further comprising purifying the recovered polypeptide.
33. A purified mammalian PAK4 serine/threonine kinase.
34. The purified mammalian PAK4 serine/threonine kinase of claim 33 which is a human PAK4 serine/threonine kinase.
35. A protein comprising substantially the amino acid sequence set forth in Figure 1A.
36. An oligonucleotide comprising a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a unique sequence included within the sequence of the isolated nucleic acid molecule encoding a PAK4 serine/threonine kinase of claim 1.
37. The oligonucleotide of claim 36, wherein the nucleic

-58-

acid is DNA.

38. The oligonucleotide of claim 36, wherein the nucleic acid is RNA.

5

39. An antisense oligonucleotide comprising a sequence capable of specifically hybridizing with a unique sequence included within the mRNA molecule of claim 5.

10

40. An antisense oligonucleotide comprising a sequence capable of specifically hybridizing with a unique sequence included within the genomic DNA molecule of claim 4.

15

41. An antibody capable of binding to the PAK4 serine/threonine kinase of claim 33 or 34.

20

42. The antibody of claim 41, wherein the antibody is a monoclonal antibody.

43. The antibody of claim 41, wherein the antibody is a polyclonal antibody.

25

44. A monoclonal antibody directed to an epitope of a PAK4 serine/threonine kinase.

30

45. A method of inhibiting PAK4 function comprising administering a ligand comprising an amino acid domain which binds to a GTP binding protein so as to inhibit binding of the GTP binding protein to PAK4.

35

46. A method of inhibiting PAK4 function comprising administering a ligand which binds to the GTP binding domain of PAK4 so as to inhibit PAK4 binding to a GTP binding protein.

47. A method of inhibiting PAK4 serine/threonine kinase

-59-

function comprising administering a ligand which blocks an ATP binding domain so as to inhibit PAK4 serine/threonine kinase function.

- 5        48. The method of any one of claims 45, 46, or 47, wherein inhibiting PAK4 function thereby inhibits polymerization of actin cytoskeleton.
- 10       49. The method of either of claims 45 or 46, wherein the GTP binding protein is Cdc42Hs or Rac.
50. The method of either of claims 45 or 46, further comprising inhibition induction of filopodia.
- 15       51. The method of either of claims 46 or 47, wherein the ligand is an antibody capable of binding to the PAK4 serine/threonine kinase.
- 20       52. The method of claim 51, wherein the antibody is a monoclonal or a polyclonal antibody.
53. A method of inhibiting growth of a tumor cell comprising blocking Cdc42Hs by administering a ligand capable of binding to a Cdc42Hs binding site of a PAK4 serine/threonine kinase.
- 25       54. The method of claim 53, wherein the tumor cell growth is inhibited in vivo or in vitro.
- 30       55. The method of claim 53, wherein the ligand is an antibody capable of binding to the PAK4 serine/threonine kinase.
56. The method of claim 55, wherein the antibody is a monoclonal or a polyclonal antibody.
- 35       57. A pharmaceutical composition comprising an amount of the oligonucleotide of any one of claims 36, 37, 38,

-60-

39, or 40 effective to prevent overexpression of a PAK4 serine/threonine kinase and a pharmaceutically acceptable carrier capable of passing through a cell membrane.

5

58. A pharmaceutical composition comprising an amount of the antibody of any one of claims 41, 42, 43 or 44 effective to block binding of a PAK4 serine/threonine kinase to a GTP binding protein and a pharmaceutically acceptable carrier capable of passing through a cell membrane.

10

59. A method of treating an abnormality in a subject, wherein the abnormality is alleviated by the inhibition of binding of a PAK4 serine/threonine kinase and a GTP binding protein which comprises administering to the subject an effective amount of the pharmaceutical composition of claim 57 effective to block binding of the PAK4 serine/threonine kinase and the GTP binding protein in the subject, thereby treating the abnormality in the subject.

15

20

60. The method of claim 59, wherein the GTP binding protein is Cdc42Hs or Rac.

25

61. The method of claim 59, wherein the abnormality is cancer or arthritis.

30

35

62. A method of treating an abnormality in a subject, wherein the abnormality is alleviated by the inhibition of binding of a PAK4 serine/threonine kinase and a GTP binding protein which comprises administering to the subject an effective amount of the pharmaceutical composition of claim 58 effective to block binding of the PAK4 serine/threonine kinase and the GTP binding protein in the subject, thereby treating the abnormality in the subject.

-61-

63. The method of claim 62, wherein the GTP binding protein is Cdc42Hs or Rac.

64. The method of claim 62, wherein the abnormality is cancer or arthritis.

1/18

FIG. 1A

1 GGCGGAGTTCAGGTCGAGCAGTTAGGCGCGGAGCGACTGGCGCGCCGAGCCGATGAGTAACCCGAAGCCCTT  
 25 TGAGGAGGGCGGAG  
 50 AGAGGAGTGGTCACCTGCCTGAGGGCATTCTGTCCACAGATCAGACCGAGCCGACCCAGTCCCGGCGCACC  
 75 ATGTTTGGGAAGAGGAAGACGGGTGGAGATCTCCGCGCCGTCCTCAACTTCGAGCACCGGTGCACACGGGCTTC  
 100 M F G K R K R V E I S A P S N F E H R V H T G F  
 125 GACCAGCACGAGCAGAAGTTACGGGGCTGCCCGCCAGTGGCAGAGCCTGATCAGAGGAGTCGGCTCGCCGGCCC  
 150 D Q H E Q K F T G L P R Q W Q S L I E S A R R P  
 175 AAGCCCTCGTCGACCCCGCTGCATCACCTCCATCCAGCCCGCGGCCCCCAAGACCATCGTGGGGGAGCAAA  
 200 K P L V D P A C I T S I Q P G A P K T I V R G S K  
 225 GGTGCCAAAGATGGGCCCCACAGCTGCTGTGGACGAGTTTGAGAACATGTCTGTGACACGCTCCCAACTCCC'TG  
 250 G A K D G A L T L L L D E F E N M S V T R S N S L  
 275 CGGAGAGACAGCCCGCCCGCCCGCTGCCCGCCAGGAAATGGGATGCCAGAGAGCCGGCCACACGGGCC  
 300 R R D S P P P A R A R Q E N G M P E P A T T A  
 325 AGAGGGGCGCCAGGGAAGGCAGCGAGCGCGGTTCGCCGTACAGCGAGGAGGTGGCGGCGAGTGGTGAC  
 350 R G G P G K A G S R G R F A G H S E A G G S G D  
 375 AGCGACGGGGGCCAGAGAGAGGCCCAAGTCTCCAGGGAGGGCTCAGGGGTCCCCAGGAGTCCCTCCCGG  
 400 R R R A G P E K R P K S S R E G S G G P Q E S S R  
 425 GACAAACGCCCTCTCCGGGCTGATGTCCGACCCCCCAGCCTGTGGTGTGGCAGTGGGGCGAAACTGGCA  
 450 D K R P L S G P D V G T P Q P A G L A S G A K L A  
 475 GCTGGCCGGCCCTTAACACCTACCCGAGGGCTGACACGGACCACCCATCCCGGGTGGCCAGGGGAGCCCTCAT  
 500 A G R P F N T Y P R A D T D H P S R G A Q G E P H  
 525 GACGTGGCCCTAACGGGCCATCAGCGGGGGCCCTGGCCATCCCCAGTCTCCTCCTCCTCCCGGCTCCC  
 550 D V A P N G P S A G G L A I P Q S S S S S R P P  
 575 ACCCGAGCCCGAGGTGCCCCAGCCCTGGAGTGTGGACCCCAACGCTCAGAGCCCCAGTGGCCCCCTCCAGCC  
 600 T R A R G A P S P G V L G P H A S E P Q L A P P A  
 625 TGCACCCCGCCGCTGCTGTTCTGGGCCCCCTGGCCCCCGTACACAGCGGGAGCCACAGCGAGTATCC  
 650 C T P A A P A V P G P P G P R S P Q R E P Q R V S  
 675 CATGAGCAGTTCGGGCTGCCCTGCAGTGGTGGTGGACCCAGGCGACCCCGCTCCTACCTGGACAACCTCATC  
 700 H E Q F R A A L Q L V D P G D P R S Y L D N F I  
 725 AAGATTGGCGAGGGCTCCACGGGCATCGTGTGATCGCCACCGTGGCGAGCTCGGGCAAGCTGGTGGCCGCTCAAG  
 750 K I G E G S T G I V C I A T V R S S G K L V A V K  
 775 AAGATGGACCTGGCGAAGCAGCAGAGCGCGAGCTGCTCTTCAACGAGGTGGTAATCATGAGGACTACCGACAC  
 800 K M D L R K O O R R E L L F N E V V I M R D Y Q H  
 825 GAGATGTGGTGGAGATGTACAACAGCTACCTGGTGGGGAGCAGGCTCTGGGTGGTCTATGGAGTTCCTTGAAGGA

2/18

FIG. 1B

1201	E N V V E M Y N S Y L V G D E L W V V M E F L E G	400
	GGCGCCCTCACCACATCGTCACCCACACCAGGATGAACGAGGACGATCGCGCCGTGTGCTTGCAGTGCTG	
1276	G A L T D I V T H T R M N E E O I A A V C L A V L	425
	CAGGCCCTGTGCTGCTCCACGCCAGGGCGTCATCCACCGGACATCAAGAGCGACTCGATCCTGCTGACCCAT	
1351	Q A L S V L H A O G V I H R D I K S D S I L L T H	450
	GATGGCAGGGTGAAGCTGTCAGACTTTGGGTTCTGCGCCAGGTGAGCAAGGAAGTGCCCGAAGGAAGTCGCTG	
1426	D G R V K L S D F G F C A O V S K E V P R R K S L	475
	GTCGGCACGCCCTACTGGATGGCCCGAGAGCTCATCTCCCGCCTTCCCTACGGGCCAGAGGTAGACATCTGGTCG	
1501	V G T P Y W M A P E L I S R L P Y G P E V D I W S	500
	CTGGGGATAATGGTGATTGAGATGGTGGACGGAGAGCCCCCTTACTTCAACGAGCCACCCCTCAAGCCATGAAG	
1576	L G I M V I E M V D G E P P Y F N E P P L K A M K	525
	ATGATTGGGACAACTGCCACCCCGACTGAAGAACCTGCACAAAGGTGTCCCATCCCTGAAGGGCTTCCTGGAC	
1651	M I R D N L P P R L K N L H K V S P S L K G F L D	550
	CGCTGTGTCGAGACCCCTGCCAGCGGGCCACGGCAGCCGAGCTGCTGAAGCACCCCATTCCTGGCCCAAGGCA	
1726	R L L V R D P A O R A T A A E L L K H P F L A K A	575
	GGCGCCCTGCCAGCATCGTGCCCTCATGCGCCAGAACCGCACCAGATGA	
	G P P A S I V P L M R Q N R T R *	591

**FIG. 1C**

FIG. 1C

	I			II			III			
PAK4	324	F I K I G E G S T G I V C I A T V R S S G K L V A V K K M D L R K Q Q R R E L L F N E V V I M R D Y	373							
PAK2	251	Y E K I G Q G A S G T V F T A T D V A L G Q E E V A I K Q I I N L Q K Q P K K E L I I N E I L V N K E L	300							
SIE20	623	L V K I G Q G A S G G V Y T A Y E I G T N V S V A I K Q H N L E K Q P K K E L I I N E I L V N K G S	672							
	IV			V			VIa			
PAK4	374	Q H E N V V E M Y N S Y L V G D E L W V V M E F L E G G A L T D L V T H T R M N E E Q I A A V C L A	423							
PAK2	301	K N P N I V N F L D S Y L V G D E L F V V M E Y L A G R S L T D V V T E T C M D E A Q I A A V C R E	350							
SIE20	674	K H P H I V M F I D S Y V L K G D L W V I M E Y M E G G S L T D V V T H C I L T E G Q I G A V C R E	723							
	VIIb			VII			VIII			
PAK4	424	V L Q A L S V L H A Q G V I H R D I K S D S I L L T H D G R V K L S D F G F C A Q V S K E V P R R K	473							
PAK2	351	C L O A L E F F L H A N Q V T H R D I K S D N V L L G M E G S V K L T D F G F C A Q I T P E Q S K R S	400							
SIE20	724	T L S G L E F L H S K G V L H R D I K S D N I L L S M E G D I K L T D F G F C A Q I N E L N L K R T	773							
	IX			IX			X			
PAK4	474	S L V G T P Y V M A P E L I S R L P Y G P E V D I W S L G I M V I E M V D G E P P Y F N E P P L K A	523							
PAK2	401	T N V G T P Y V M A P E V V T R K A Y G P K V D I W S L G I M A I E M V E G E P P Y L N E N P L R A	450							
SIE20	774	T H V G T P Y V M A P E V V S E R E Y G P K V D I W S L G I M I I E M I E G E P P Y L N E T P L R A	823							
	X			XI			XI			
PAK4	524	M K M I R K N L P P R L K N L H K V S P S L K G F F L D R L L V R D P A Q R A T A A E L L K H P F L A	573							
PAK2	451	L Y L I A T N G T P E L Q K P E K L S P I F R D F L N R C L E M D V E K R G S A K E L L Q H P F L K	500							
SIE20	824	L Y L I A T N G T P K L K E P E N L S S S L K K F F L D W C L C V E P E D R A S A T E L L H D E Y I T	873							


4/18

FIG. 1D

PAK4	10	EISAPSNFEHRVHTGFDQHEQ	30
PAK2	71	EISPPSDFEHTIHVGFDVAVTG	91
STE20	317	ISYNA---KHIIHVGVDSTG	362
WASP	238	DIGAPSGFKHVS HVGWDPQNG	258
CLA4	183	GVSSPTNFTHKVHVGFDPETG	203

5/18

FIG. 1E



6/18

FIG. 2A







FIG. 2B







**FIG. 3C**



**FIG. 3D**



**FIG. 3E**



8/18

Actin

FIG. 4B




FIG. 4D




Anti-IL1A

FIG. 4A PAK4



PAK4/  
CDC42Hsv12

FIG. 4C



9/18

Actin




FIG. 4F

Anti-HA




FIGURE 4

FIG. 4E

10/18

FIG. 4H



FIG. 4G




11/18

FIG. 4J



FIG. 4I



12/18


FIG. 5B

Anti- $\beta$ -COP



FIG. 5D

PAK4/  
BFA



Anti-HA




FIG. 5A

PAK4/  
BFA




FIG. 5C

FIG. 5F



Anti-HA




FIG. 5E





FIG. 5H




FIG. 5G

14/18




15/18



16/18

FIG. 7A



17/18

FIG. 7B


Anti HA

PAK4 + Cdc42L61C40



FIG. 7C

PAK4



18/18

**FIG. 8A** Partial cDNA of the mouse PAK4:

AAGCAGCAGC GCGCGAGTT GCTCTTCAAT GAGGTGGTGA TCATGCGGGA  
 CTACCGGCAC GAGAACGTGG TGGAGATGTA CAACAGCTAC CTGGTGGGTG  
 ACGAACTCTG GGTGTCATG GAGTTCCTGG AAGCGGGCGC CCTCACGGAT  
 ATTGTCACCC ACACAGGAT GAACGAGGAA CAGATCGCCG CCGTGTGCCCT  
 GGCTGTGCTT CAGGCGCTGG CTGTGCTCCA CGCCACGGGT GTCATCCACA  
 GCGACATAAA AACGGACA

**FIG. 8B** predicted amino acid sequence of the partial mouse PAK4 cDNA:

KQQRRELLFN EVVIMRDYR HENVVEMYNSY LVGDELWVVM EFLEGGALTD  
 IVTHTRMNEEQIAAVCLAVLQALAVLHAQG VIHSDIKTD

**FIG. 8C** Partial genomic sequence of mouse PAK4:

ACCTGGTGGG TGACGAACTC TGGGTCGTCA TGGAGTTCCT GGAAGGCGGC  
 GGCCTCACGG ATATTGTCAC CCACACCAGG TACCATAGGG CAGCCTGCTG  
 GCTCATGTGC TCCCTGGGT GGAAGTGGGA CCTTTAGGC TCTGGTGATA  
 GACAAAGTGCC CTCCAGAGTG TGGGTGGGC AGTGAGGCCA GGCACACAGG  
 ATGGGGGTCA TAGCATCGTG GCTCCCTGAC CCTGTTGAG GCGGGTCTTT  
 GTGACCTCTT GTGTCTAA GCAGGGTAGG GGCTCTTCA CTGCCCACTC  
 TCACCCACAG GTGGGATGCC CAAGCAGCG CTGAGTGCCC AGTTGCTCCT  
 CTGCCCGCGC AGGATGAACG AGGAACAGAT CGCCGCCCGT GTGCCCTGGCT  
 TGTGCTTCAN GCGCTGGCTT GTGCTCCACG CCCAGGGTGT CATCCACCGT  
 GACATCAAGA GTGACTCTAT CTTGCTGACC CATGATGGC

## SEQUENCE LISTING

<110> The Trustees of Columbia University in the City of

<120> PAK4, A NOVEL GENE ENCODING A SERINE/THREONINE KINASE

<130> 0575/55311-A-PCT

<140> NOT YET KNOWN

<141> 1999-05-21

<150> 09/082,737

<151> 1998-05-21

<160> 17

<170> PatentIn Ver. 2.0 - beta

<210> 1

<211> 1941

<212> DNA

<213> Homo sapiens

<400> 1

```

tgagggaggc gcgagggcgc ggagttccag gtcgagcagt taggccgcga gcgactgcgg 60
cgccgagccg atgagtaacc cgaagcccct agaggagtgg tcacctgcct gagggcactt 120
ctgtcccacc agcatcagac caggccgcac cgagtccccg gcaccatgtt tgggaagagg 180
aagaagcggg tggagatctc cgcgccgtcc aacttcgagc accgctgca cacgggcttc 240
gaccagcacg agcagaagtt cacggggctg ccccgccagt ggcagagcct gatcgaggag 300
tcggctcgcc ggcccaagcc cctcgtcgac cccgcctgca tcacctccat ccagcccggg 360
gcccccaaga ccatcgtgcg gggcagcaaa ggtgccaaaag atggggccct cacgctgctg 420
ctggacgagt ttgagaacat gtcggtgaca cgctccaact ccctgcggag agacagcccg 480
ccgcccggcg cccgtgcccg ccaggaaaat gggatgccag aggagccggc caccacggcc 540
agagggggcc caggaaggc aggcagccga ggccggttcg ccggtcacag cgaggcaggt 600
ggcggcagtg gtgacaggcg acgggcgggg ccagagaaga ggcccaagtc ttccagggag 660
ggctcagggg gtccccagga gtctcccgg gacaaacgcc ccctctccgg gcctgatgtc 720
ggcacccccc agcctgctgg tctggccagt ggggcgaaac tggcagctgg ccggcccttt 780
aacacctacc cgagggtga cacggaccac ccatcccggg gtgcccaggg ggagcctcat 840
gacgtggccc ctaacggggc atcagcgggg ggcttgcca tccccagtc ctctcctcc 900
tcctcccggc ctcccaccg agcccgaggt gccccagcc ctggagtgtt gggacccac 960
gcctcagagc cccagctggc ccctccagcc tgcacccccg ccgcccctgc tgttcctggg 1020
ccccctggcc cccgtcacc acagcgggag ccacagcgag tatcccatga gcagttccgg 1080
gctgccctgc agctggtggt ggaccaggc gacccccgt cctacctgga caacttcac 1140
aagattggcg agggctccac gggcatcgtg tgcacgccca ccgtgcgcag ctggggcaag 1200
ctggtggccg tcaagaagat ggacctgcgc aagcagcaga ggcgcgagct gctcttcaac 1260
gaggtggtaa tcatgagggg ctaccagcac gagaatgtgg tggagatgta caacagctac 1320
ctggtggggg acgagctctg ggtggtcatg gagttcctgg aaggaggcgc cctcaccgac 1380
atcgtcacc acaccaggat gaacgaggag cagatcgcg ccgtgtgcct tgcagtgtc 1440
caggccctgt cggtgctcca cgcccagggc gtcacccacc gggacatcaa gagcgactcg 1500
atcctgctga cccatgatgg cagggtgaag ctgtcagact ttgggttctg cgcccagggtg 1560

```

```

agcaaggaag tgccccgaag gaagtcgctg gtcggcagcg cctactggat ggccccagag 1620
ctcatctccc gccttcccta cggggccagag gtagacatct ggtcgctggg gataatggtg 1680
attgagatgg tggacggaga gccccctac ttcaacgagc caccctcaa agccatgaag 1740
atgattcggg acaacctgcc acccgactg aagaacctgc acaagggtgc gccatccctg 1800
aagggcttcc tggaccgcct gctggtgcga gacctgccc agcggggccac ggagcccgag 1860
ctgctgaagc acccattcct ggccaaggca gggcgcctg ccagcatcgt gcccctcatg 1920
cgccagaacc gcaccagatg a 1941

```

&lt;210&gt; 2

&lt;211&gt; 591

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

```

Met Phe Gly Lys Arg Lys Lys Arg Val Glu Ile Ser Ala Pro Ser Asn
  1             5             10             15

```

```

Phe Glu His Arg Val His Thr Gly Phe Asp Gln His Glu Gln Lys Phe
      20             25             30

```

```

Thr Gly Leu Pro Arg Gln Trp Gln Ser Leu Ile Glu Glu Ser Ala Arg
      35             40             45

```

```

Arg Pro Lys Pro Leu Val Asp Pro Ala Cys Ile Thr Ser Ile Gln Pro
      50             55             60

```

```

Gly Ala Pro Lys Thr Ile Val Arg Gly Ser Lys Gly Ala Lys Asp Gly
      65             70             75             80

```

```

Ala Leu Thr Leu Leu Leu Asp Glu Phe Glu Asn Met Ser Val Thr Arg
      85             90             95

```

```

Ser Asn Ser Leu Arg Arg Asp Ser Pro Pro Pro Pro Ala Arg Ala Arg
      100            105            110

```

```

Gln Glu Asn Gly Met Pro Glu Glu Pro Ala Thr Thr Ala Arg Gly Gly
      115            120            125

```

```

Pro Gly Lys Ala Gly Ser Arg Gly Arg Phe Ala Gly His Ser Glu Ala
      130            135            140

```

```

Gly Gly Gly Ser Gly Asp Arg Arg Arg Ala Gly Pro Glu Lys Arg Pro
      145            150            155            160

```

```

Lys Ser Ser Arg Glu Gly Ser Gly Gly Pro Gln Glu Ser Ser Arg Asp
      165            170            175

```

```

Lys Arg Pro Leu Ser Gly Pro Asp Val Gly Thr Pro Gln Pro Ala Gly
      180            185            190

```

```

- Leu Ala Ser Gly Ala Lys Leu Ala Ala Gly Arg Pro Phe Asn Thr Tyr
    195                200                205

Pro Arg Ala Asp Thr Asp His Pro Ser Arg Gly Ala Gln Gly Glu Pro
    210                215                220

His Asp Val Ala Pro Asn Gly Pro Ser Ala Gly Gly Leu Ala Ile Pro
    225                230                235                240

Gln Ser Ser Ser Ser Ser Ser Arg Pro Pro Thr Arg Ala Arg Gly Ala
    245                250                255

Pro Ser Pro Gly Val Leu Gly Pro His Ala Ser Glu Pro Gln Leu Ala
    260                265                270

Pro Pro Ala Cys Thr Pro Ala Ala Pro Ala Val Pro Gly Pro Pro Gly
    275                280                285

Pro Arg Ser Pro Gln Arg Glu Pro Gln Arg Val Ser His Glu Gln Phe
    290                295                300

Arg Ala Ala Leu Gln Leu Val Val Asp Pro Gly Asp Pro Arg Ser Tyr
    305                310                315                320

Leu Asp Asn Phe Ile Lys Ile Gly Glu Gly Ser Thr Gly Ile Val Cys
    325                330                335

Ile Ala Thr Val Arg Ser Ser Gly Lys Leu Val Ala Val Lys Lys Met
    340                345                350

Asp Leu Arg Lys Gln Gln Arg Arg Glu Leu Leu Phe Asn Glu Val Val
    355                360                365

Ile Met Arg Asp Tyr Gln His Glu Asn Val Val Glu Met Tyr Asn Ser
    370                375                380

Tyr Leu Val Gly Asp Glu Leu Trp Val Val Met Glu Phe Leu Glu Gly
    385                390                395                400

Gly Ala Leu Thr Asp Ile Val Thr His Thr Arg Met Asn Glu Glu Gln
    405                410                415

Ile Ala Ala Val Cys Leu Ala Val Leu Gln Ala Leu Ser Val Leu His
    420                425                430

Ala Gln Gly Val Ile His Arg Asp Ile Lys Ser Asp Ser Ile Leu Leu
    435                440                445

Thr His Asp Gly Arg Val Lys Leu Ser Asp Phe Gly Phe Cys Ala Gln
    450                455                460

```

Val Ser Lys Glu Val Pro Arg Arg Lys Ser Leu Val Gly Thr Pro Tyr  
465 470 475 480

Trp Met Ala Pro Glu Leu Ile Ser Arg Leu Pro Tyr Gly Pro Glu Val  
485 490 495

Asp Ile Trp Ser Leu Gly Ile Met Val Ile Glu Met Val Asp Gly Glu  
500 505 510

Pro Pro Tyr Phe Asn Glu Pro Pro Leu Lys Ala Met Lys Met Ile Arg  
515 520 525

Asp Asn Leu Pro Pro Arg Leu Lys Asn Leu His Lys Val Ser Pro Ser  
530 535 540

Leu Lys Gly Phe Leu Asp Arg Leu Leu Val Arg Asp Pro Ala Gln Arg  
545 550 555 560

Ala Thr Ala Ala Glu Leu Leu Lys His Pro Phe Leu Ala Lys Ala Gly  
565 570 575

Pro Pro Ala Ser Ile Val Pro Leu Met Arg Gln Asn Arg Thr Arg  
580 585 590

<210> 3

<211> 250

<212> PRT

<213> Homo sapiens

<400> 3

Phe Ile Lys Ile Gly Glu Gly Ser Thr Gly Ile Val Cys Ile Ala Thr  
1 5 10 15

Val Arg Ser Ser Gly Lys Leu Val Ala Val Lys Lys Met Asp Leu Arg  
20 25 30

Lys Gln Gln Arg Arg Glu Leu Leu Phe Asn Glu Val Val Ile Met Arg  
35 40 45

Asp Tyr Gln His Glu Asn Val Val Glu Met Tyr Asn Ser Tyr Leu Val  
50 55 60

Gly Asp Glu Leu Trp Val Val Met Glu Phe Leu Glu Gly Gly Ala Leu  
65 70 75 80

Thr Asp Ile Val Thr His Thr Arg Met Asn Glu Glu Gln Ile Ala Ala  
85 90 95

```

Val Cys Leu Ala Val Leu Gln Ala Leu Ser Val Leu His Ala Gln Gly
      100                      105                      110

Val Ile His Arg Asp Ile Lys Ser Asp Ser Ile Leu Leu Thr His Asp
      115                      120                      125

Gly Arg Val Lys Leu Ser Asp Phe Gly Phe Cys Ala Gln Val Ser Lys
      130                      135                      140

Glu Val Pro Arg Arg Lys Ser Leu Val Gly Thr Pro Tyr Trp Met Ala
145                      150                      155                      160

Pro Glu Leu Ile Ser Arg Leu Pro Tyr Gly Pro Glu Val Asp Ile Trp
      165                      170                      175

Ser Leu Gly Ile Met Val Ile Glu Met Val Asp Gly Glu Pro Pro Tyr
      180                      185                      190

Phe Asn Glu Pro Pro Leu Lys Ala Met Lys Met Ile Arg Lys Asn Leu
      195                      200                      205

Pro Pro Arg Leu Lys Asn Leu His Lys Val Ser Pro Ser Leu Lys Gly
      210                      215                      220

Phe Leu Asp Arg Leu Leu Val Arg Asp Pro Ala Gln Arg Ala Thr Ala
225                      230                      235                      240

Ala Glu Leu Leu Lys His Pro Phe Leu Ala
      245                      250

```

```

<210> 4
<211> 250
<212> PRT
<213> Homo sapiens

```

```

<400> 4
Tyr Glu Lys Ile Gly Gln Gly Ala Ser Gly Thr Val Phe Thr Ala Thr
  1              5              10              15

Asp Val Ala Leu Gly Gln Glu Val Ala Ile Lys Gln Ile Asn Leu Gln
      20              25              30

Lys Gln Pro Lys Lys Glu Leu Ile Ile Asn Glu Ile Leu Val Met Lys
      35              40              45

Glu Leu Lys Asn Pro Asn Ile Val Asn Phe Leu Asp Ser Tyr Leu Val
      50              55              60

Gly Asp Glu Leu Phe Val Val Met Glu Tyr Leu Ala Gly Arg Ser Leu

```

```
<210> 5
<211> 250
<212> PRT
<213> Yeast
```

<400> 5  
Leu Val Lys Ile Gly Gln Gly Ala Ser Gly Gly Val Tyr Thr Ala Tyr  
1 5 10 15  
Glu Ile Gly Thr Asn Val Ser Val Ala Ile Lys Gln Met Asn Leu Glu  
20 25 30  
Lys Gln Pro Lys Lys Glu Leu Ile Ile Asn Glu Ile Leu Val Met Lys  
35 40 45

Gly Ser Lys His Pro Asn Ile Val Asn Phe Ile Asp Ser Tyr Val Leu  
 50 55 60  
 Lys Gly Asp Leu Trp Val Ile Met Glu Tyr Met Glu Gly Gly Ser Leu  
 65 70 75 80  
 Thr Asp Val Val Thr His Cys Ile Leu Thr Glu Gly Gln Ile Gly Ala  
 85 90 95  
 Val Cys Arg Glu Thr Leu Ser Gly Leu Glu Phe Leu His Ser Lys Gly  
 100 105 110  
 Val Leu His Arg Asp Ile Lys Ser Asp Asn Ile Leu Leu Ser Met Glu  
 115 120 125  
 Gly Asp Ile Lys Leu Thr Asp Phe Gly Phe Cys Ala Gln Ile Asn Glu  
 130 135 140  
 Leu Asn Leu Lys Arg Thr Thr Met Val Gly Thr Pro Tyr Trp Met Ala  
 145 150 155 160  
 Pro Glu Val Val Ser Arg Lys Glu Tyr Gly Pro Lys Val Asp Ile Trp  
 165 170 175  
 Ser Leu Gly Ile Met Ile Ile Glu Met Ile Glu Gly Glu Pro Pro Tyr  
 180 185 190  
 Leu Asn Glu Thr Pro Leu Arg Ala Leu Tyr Leu Ile Ala Thr Asn Gly  
 195 200 205  
 Thr Pro Lys Leu Lys Glu Pro Glu Asn Leu Ser Ser Ser Leu Lys Lys  
 210 215 220  
 Phe Leu Asp Trp Cys Leu Cys Val Glu Pro Glu Asp Arg Ala Ser Ala  
 225 230 235 240  
 Thr Glu Leu Leu His Asp Glu Tyr Ile Thr  
 245 250

&lt;210&gt; 6

&lt;211&gt; 21

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 6

Glu Ile Ser Ala Pro Ser Asn Phe Glu His Arg Val His Thr Gly Phe  
 1 5 10 15

Asp Gln His Glu Gln  
20

<210> 7  
<211> 21  
<212> PRT  
<213> Homo sapiens

<400> 7  
Glu Ile Ser Pro Pro Ser Asp Phe Glu His Thr Ile His Val Gly Phe  
1 5 10 15

Asp Ala Val Thr Gly  
20

<210> 8  
<211> 18  
<212> PRT  
<213> Yeast

<400> 8  
Ile Ser Tyr Asn Ala Lys His Ile His His Val Gly Val Asp Ser Lys  
1 5 10 15

Thr Gly

<210> 9  
<211> 21  
<212> PRT  
<213> Homo sapiens

<400> 9  
Asp Ile Gly Ala Pro Ser Gly Phe Lys His Val Ser His Val Gly Trp  
1 5 10 15

Asp Pro Gln Asn Gly  
20

<210> 10  
<211> 21  
<212> PRT  
<213> Yeast

<400> 10  
Gly Val Ser Ser Pro Thr Asn Phe Thr His Lys Val His Val Gly Phe

1 5 10 15

Asp Pro Glu Thr Gly  
20

<210> 11  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 11  
Lys Lys Glu Leu Ile Ile Asn Glu  
1 5

<210> 12  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 12  
Val Gly Thr Pro Tyr Trp Met Ala  
1 5

<210> 13  
<211> 268  
<212> DNA  
<213> Mouse

<400> 13  
aagcagcagc ggcgcgagtt gctcttcaat gaggtggtga tcatgcggga ctaccggcac 60  
gagaacgtgg tggagatgta caacagctac ctggtgggtg acgaactctg ggtcgtcatg 120  
gagttcctgg aaggcggcgc cctcacggat attgtcaccc acaccaggat gaacgaggaa 180  
cagatcgccg ccgtgtgcct ggctgtgctt caggcgctgg ctgtgctcca cgcccagggt 240  
gtcatccaca gcgacataaa aacggaca 268

<210> 14  
<211> 89  
<212> PRT  
<213> Mouse

<400> 14

Lys Gln Gln Arg Arg Glu Leu Leu Phe Asn Glu Val Val Ile Met Arg  
 1 5 10 15  
 Asp Tyr Arg His Glu Asn Val Val Glu Met Tyr Asn Ser Tyr Leu Val  
 20 25 30  
 Gly Asp Glu Leu Trp Val Val Met Glu Phe Leu Glu Gly Gly Ala Leu  
 35 40 45  
 Thr Asp Ile Val Thr His Thr Arg Met Asn Glu Glu Gln Ile Ala Ala  
 50 55 60  
 Val Cys Leu Ala Val Leu Gln Ala Leu Ala Val Leu His Ala Gln Gly  
 65 70 75 80  
 Val Ile His Ser Asp Ile Lys Thr Asp  
 85

<210> 15  
 <211> 489  
 <212> DNA  
 <213> Mouse

<400> 15  
 acctggtggg tgacgaactc tgggtcgtca tggagttcct ggaaggcggc gccctcacgg 60  
 atattgtcac ccacaccagg taccataggg cagcctgctg gctcatgtgc tccctggggg 120  
 ggaactggga cccttttaggc tctggtgata gacaagtgcc ctccagagtg tgggtggggc 180  
 agtgaggcca ggcacacagg atgggggtca tagcatcgtg gctccctgac ccctgttgag 240  
 gcgggtcttt gtgacctctt gttgtctaaa gcagggtagg ggccctcttca ctgcccactc 300  
 tcaccccagg gtgggatgcc caaggcagcg ctgagtgcc agttgctcct ctgcccgcgc 360  
 aggatgaacg aggaacagat cgccgcccgt gtgcctggct tgtgttcan gcgctggctt 420  
 gtgctccacg cccagggtgt catccaccgt gacatcaaga gtgactctat cttgctgacc 480  
 catgatggc 489

<210> 16  
 <211> 6  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Primer

<400> 16  
 Gly Glu Gly Ser Thr Gly  
 1 5

<210> 17  
 <211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 17

Ser Leu Val Gly Thr Pro

1

5

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/11341

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : C12N 15/00, 5/00, 1/20, 9/14; C07H 21/04; C12Q 1/68

US CL : 435/6, 194, 325, 252.3; 536/23.2

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 194, 325, 252.3; 536/23.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, SCISEARCH, BIOTECHDS, LIFESCI, MEDLINE, EMBASE, BIOSIS, NTIS

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BROWN et al. Human Ste20 homologue hPAK1 links GTPase to JNK MAP kinase pathway. Curr. Biol. 01 May 1996, Vol.6, pages 598-605, see the entire article specially the abstract.	1-40
X	Sigma catalog, 'Biochemicals Organic Compounds for Research and Diagnostic Reagents' "Anonymous" ALA-VAL fragment, page 64, compare this fragment to amino acids 422-423 of PAK4 kinase.	17

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

*A*	document defining the general state of the art which is not considered to be of particular relevance	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*B*	earlier document published on or after the international filing date	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*L*	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*O*	document referring to an oral disclosure, use, exhibition or other means	*Z*	document member of the same patent family
*P*	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

31 AUGUST 1999

Date of mailing of the international search report

05 NOV 1999

 Name and mailing address of the ISA/US  
 Commissioner of Patents and Trademarks  
 Box PCT  
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MARYAM MONSHIPOURI

Telephone No. (703) 308-0196

 JOYCE BRIDGERS  
 PARALEGAL SPECIALIST  
 CHEMICAL MATRIX

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/11341

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HARDEN et al. A Drosophila homolog of the Rac- and Cdc42-activated serine/threonine kinase PAK is a potential focal adhesion and focal complex protein that colocalizes with dynamic actin structures. Mol. Cell. Biol. 01 May 1996, Vol.16, pages 1896-1908, see their substantially the same amino acid sequence to amino acids 11-585 of SEQ ID NO:2.	10, 35
X	Database EST, Accession No. R18825, HILLIER et al. 'yg22e03.r1 Soars infant brain INIB Homo sapiens cDNA clone IMAGE:32974 5' similar to SP:KPAK-RAT p35465', 14 April 1995, see their sequence for oligos of more than 15 nucleotides in length which specifically hybridizes to sequences encoding PAK4 kinase.	36-37

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/11341

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-40

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/11341

### BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This international searching authority has found 5 inventions claimed in the international application covered by the claims indicated below:

Group I, claims 1-40, drawn to isolated nucleic acid molecules encoding a PAK4 serine/threonine kinase, vectors comprising the nucleic acids, methods of producing a PAK4 serine/threonine kinase, fusion proteins comprising the kinase, as well as hybridization probes and antisense oligonucleotides comprising of sequences capable of specifically hybridizing to DNA molecules encoding PAK4 kinase.

Group II, claims 41-44, drawn to antibodies capable of binding to PAK4 kinase.

Group III, claims 45-52, drawn to a method of inhibiting PAK4 function comprising administering a ligand which binds to GTP binding protein so as to inhibit binding to the GTP binding protein to PAK4.

Group IV, claims 53-56, drawn to a method of inhibiting a tumor cell growth comprising blocking Cdc42Hs by administering a ligand capable of binding Cdc42Hs binding site of PAK4 kinase.

Group V, claims 57-64, drawn to a method of treating an abnormality in a subject, wherein the abnormality is alleviated by the inhibition of PAK4 binding and a GTP binding protein which comprises administering to the subject an effective amount of pharmaceutical composition comprising oligonucleotides which specifically hybridize to those encoding PAK4 kinase as well as pharmaceutical compositions comprising such oligonucleotides.

The inventions listed as Groups I-V do not relate to a single inventive concept because they are 5 different categories of invention and are not drawn to combinations of categories (i.e. categories 1-5), specified in 37 CFR section 1.475(b).

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**This Page Blank (uspto)**